patientBarCode_OLD	sampleID_OLD	domainID	ConceptID 	StudyID	samplingTherapies	samplingTherapiesConceptID	samplingTherapiesResponse	3dpucai_ignore	5dpucai_ignore	inflix8wk	inflix30wk	Immunotherapy	ImmunotherapyConceptID	Immunosupp	ImmunosuppConceptID	steroid_therapy	SteroidTherapyConceptID	OtherTher	patientBarCode	sampleID_new	3dpucai_STRESC_ignore	3dpucai_STRESN_ignore	5dpucai_STRESC_ignore	5dpucai_STRESN_ignore	NOTES	CMTRT_sampling	CMDOSTXT_sampling	CMLNKID	CMLNKGRP	CMTRT_foll	CMDOSE_foll	CMDOSU_foll	CMTRT_declined	CMDY_foll	samplingTherapiesResponse_1	samplingTherapiesResponse_STRESC	follTherResponse_1	follTherResponse_STRESC	RSGRPID	RSLNKGRP	RSMETHOD	RSMETHOD1	RSMETHOD2	RSMETHOD3	RSMETHOD1_GSE21231	RSMETHOD2_GSE21231	CMROUTE_sampling	CMROUTE_foll	CMDOSFRM_foll	sample	sampleDescription	HOOCCUR	HODY	SUPPHO_QVAL	inflix8wk_1	inflix8wk_STRESC	inflix30wk_1	inflix30wk_STRESC	RSMETHOD_GSE23597	RSMETHOD1_GSE23597	RSMETHOD2_GSE23597	EXTRT	EXOCCUR	EXDOSE	EXDOSU	EXDOSFRQ	EXROUTE	EXGRPID	EXLNKGRP	EXTPTNUM	EXTPT	EXELTM	EXTPTREF	EXDY
-		1	1457228	GSE22619															IBD-03620	IBD-03620-SCLN-01						CORTICOSTEROIDS			N1																																													
-		1	1457228	GSE22619															IBD-03620	IBD-03620-SCLN-01						IMMUNOMODULATOR			N1																																													
-		1	1457228	GSE22619															IBD-03621	IBD-03621-SCLN-01						CORTICOSTEROIDS			N1																																													
-		1	1457228	GSE22619															IBD-03621	IBD-03621-SCLN-01						IMMUNOMODULATOR			N1																																													
IBD-00005	IBD-00005-CLN-01	1	1457228	GSE2461															IBD-00005	IBD-00005-CLN-01																																																						
IBD-00022	IBD-00022-CLN-01	1	1457228	GSE4183															IBD-00022	IBD-00022-CLN-01																																																						
IBD-00023	IBD-00023-CLN-01	1	1457228	GSE4183															IBD-00023	IBD-00023-CLN-01																																																						
IBD-00024	IBD-00024-SCLN-01	1	1457228	GSE4183															IBD-00024	IBD-00024-SCLN-01																																																						
IBD-00025	IBD-00025-CLN-01	1	1457228	GSE4183															IBD-00025	IBD-00025-CLN-01																																																						
IBD-00026	IBD-00026-CLN-01	1	1457228	GSE4183															IBD-00026	IBD-00026-CLN-01																																																						
IBD-00027	IBD-00027-SCLN-01	1	1457228	GSE4183															IBD-00027	IBD-00027-SCLN-01																																																						
IBD-00028	IBD-00028-CLN-01	1	1457228	GSE4183															IBD-00028	IBD-00028-CLN-01																																																						
IBD-00029	IBD-00029-CLN-01	1	1457228	GSE4183															IBD-00029	IBD-00029-CLN-01																																																						
IBD-00030	IBD-00030-SCLN-01	1	1457228	GSE4183															IBD-00030	IBD-00030-SCLN-01																																																						
IBD-00038	IBD-00038-CLN-01	1	1457228	GSE10714															IBD-00038	IBD-00038-CLN-01																																																						
IBD-00039	IBD-00039-CLN-01	1	1457228	GSE10714															IBD-00039	IBD-00039-CLN-01																																																						
IBD-00040	IBD-00040-CLN-01	1	1457228	GSE10714															IBD-00040	IBD-00040-CLN-01																																																						
IBD-00046	IBD-00046-WB-01	1	1457228	GSE11499															IBD-00046	IBD-00046-PB-01																																																						
IBD-00047	IBD-00047-WB-01	1	1457228	GSE11499															IBD-00047	IBD-00047-PB-01																																																						
IBD-00048	IBD-00048-WB-01	1	1457228	GSE11499															IBD-00048	IBD-00048-PB-01																																																						
IBD-00049	IBD-00049-WB-01	1	1457228	GSE11499															IBD-00049	IBD-00049-PB-01																																																						
IBD-00050	IBD-00050-WB-01	1	1457228	GSE11499															IBD-00050	IBD-00050-PB-01																																																						
IBD-00051	IBD-00051-WB-01	1	1457228	GSE11499															IBD-00051	IBD-00051-PB-01																																																						
IBD-00096	IBD-00096-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00096	IBD-00096-REC-01					UC-32	MESALAMINE			W1																																													
IBD-00120	IBD-00120-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00096	IBD-00096-CLN-02					UC-32	MESALAMINE			W1																																													
IBD-00097	IBD-00097-CLN-01	1	1457228	GSE6731	Corticosteroids	259627										Corticosteroids	259627		IBD-00097	IBD-00097-REC-01					UC-35	CORTICOSTEROIDS			W1																																													
IBD-00097	IBD-00097-CLN-01	1	1457228	GSE6731	Immunomodulator	271591								Immunomodulator, NOS	271591				IBD-00097	IBD-00097-REC-01					UC-35	IMMUNOMODULATOR			W1																																													
IBD-00121	IBD-00121-CLN-01	1	1457228	GSE6731	Corticosteroids	259627										Corticosteroids	259627		IBD-00097	IBD-00097-ACLN-02					UC-35	CORTICOSTEROIDS			W1																																													
IBD-00121	IBD-00121-CLN-01	1	1457228	GSE6731	Immunomodulator	271591								Immunomodulator, NOS	271591				IBD-00097	IBD-00097-ACLN-02					UC-35	IMMUNOMODULATOR			W1																																													
IBD-00098	IBD-00098-CLN-01	1	1457228	GSE6731	Corticosteroids	259627										Corticosteroids	259627		IBD-00098	IBD-00098-SCLN-01					UC-38	CORTICOSTEROIDS			W1																																													
IBD-00098	IBD-00098-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00098	IBD-00098-SCLN-01					UC-38	MESALAMINE			W1																																													
IBD-00122	IBD-00122-CLN-01	1	1457228	GSE6731	Corticosteroids	259627										Corticosteroids	259627		IBD-00098	IBD-00098-ACLN-02					UC-38	CORTICOSTEROIDS			W1																																													
IBD-00122	IBD-00122-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00098	IBD-00098-ACLN-02					UC-38	MESALAMINE			W1																																													
IBD-00099	IBD-00099-CLN-01	1	1457228	GSE6731	Immunomodulator	271591								Immunomodulator, NOS	271591				IBD-00099	IBD-00099-REC-01					UC-55	IMMUNOMODULATOR			W1																																													
IBD-00099	IBD-00099-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00099	IBD-00099-REC-01					UC-55	MESALAMINE			W1																																													
IBD-00123	IBD-00123-CLN-01	1	1457228	GSE6731	Immunomodulator	271591								Immunomodulator, NOS	271591				IBD-00099	IBD-00099-HFCLN-02					UC-55	IMMUNOMODULATOR			W1																																													
IBD-00123	IBD-00123-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00099	IBD-00099-HFCLN-02					UC-55	MESALAMINE			W1																																													
IBD-00100	IBD-00100-CLN-01	1	1457228	GSE6731	Mesalamine	255222												Mesalamine	IBD-00100	IBD-00100-SCLN-01						MESALAMINE			W1																																													
IBD-00124	IBD-00124-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00124	IBD-00124-CLN-01																			P1	Q1										GSM578739	P12/5mg/kg/W0 (36384)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00124	IBD-00124-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00124	IBD-00124-CLN-01																			P1	Q1										GSM578739	P12/5mg/kg/W0 (36384)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00124	IBD-00124-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00124	IBD-00124-CLN-01																			P1	Q1										GSM578739	P12/5mg/kg/W0 (36384)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00125	IBD-00125-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00125	IBD-00125-CLN-01																			P1	Q1										GSM578811	P43/5mg/kg/W0 (36506)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00125	IBD-00125-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00125	IBD-00125-CLN-01																			P1	Q1										GSM578811	P43/5mg/kg/W0 (36506)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00125	IBD-00125-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00125	IBD-00125-CLN-01																			P1	Q1										GSM578811	P43/5mg/kg/W0 (36506)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00126	IBD-00126-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00126	IBD-00126-CLN-01																			P1	Q1										GSM578821	P47/5mg/kg/W0 (36517)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00126	IBD-00126-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00126	IBD-00126-CLN-01																			P1	Q1										GSM578821	P47/5mg/kg/W0 (36517)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00126	IBD-00126-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00126	IBD-00126-CLN-01																			P1	Q1										GSM578821	P47/5mg/kg/W0 (36517)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00127	IBD-00127-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00127	IBD-00127-CLN-03																			P1	Q1										GSM578825	P49/5mg/kg/W30 (36521)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00127	IBD-00127-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00127	IBD-00127-CLN-03																			P1	Q1										GSM578825	P49/5mg/kg/W30 (36521)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00127	IBD-00127-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00127	IBD-00127-CLN-03																			P1	Q1										GSM578825	P49/5mg/kg/W30 (36521)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00127	IBD-00127-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00127	IBD-00127-CLN-03																			P1	Q1										GSM578825	P49/5mg/kg/W30 (36521)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00128	IBD-00128-CLN-01	1	1457228	GSE23597	Infliximab	487061				 	 	Infliximab	487061						IBD-00128	IBD-00128-CLN-01																														GSM578803	P39/Placebo/W0 (36497)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00128	IBD-00128-CLN-01	1	1457228	GSE23597	Infliximab	487061				 	 	Infliximab	487061						IBD-00128	IBD-00128-CLN-01																														GSM578803	P39/Placebo/W0 (36497)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00128	IBD-00128-CLN-01	1	1457228	GSE23597	Infliximab	487061				 	 	Infliximab	487061						IBD-00128	IBD-00128-CLN-01																														GSM578803	P39/Placebo/W0 (36497)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00129	IBD-00129-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00129	IBD-00129-CLN-01																														GSM578787	P31/Placebo/W8 (36461)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00129	IBD-00129-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00129	IBD-00129-CLN-01																														GSM578787	P31/Placebo/W8 (36461)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00129	IBD-00129-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00129	IBD-00129-CLN-01																														GSM578787	P31/Placebo/W8 (36461)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00129	IBD-00129-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00129	IBD-00129-CLN-01																														GSM578787	P31/Placebo/W8 (36461)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00184	IBD-00184-SCLN-01	1	1457228	GSE1710															IBD-00184	IBD-00184-SCLN-01																																																						
IBD-00185	IBD-00185-SCLN-01	1	1457228	GSE1710															IBD-00185	IBD-00185-SCLN-01																																																						
IBD-00186	IBD-00186-SCLN-01	1	1457228	GSE1710															IBD-00186	IBD-00186-SCLN-01																																																						
IBD-00187	IBD-00187-SCLN-01	1	1457228	GSE1710															IBD-00187	IBD-00187-SCLN-01																																																						
IBD-00188	IBD-00188-SCLN-01	1	1457228	GSE1710															IBD-00188	IBD-00188-SCLN-01																																																						
IBD-00189	IBD-00189-SCLN-01	1	1457228	GSE1710															IBD-00189	IBD-00189-SCLN-01																																																						
IBD-00190	IBD-00190-SCLN-01	1	1457228	GSE1710															IBD-00190	IBD-00190-SCLN-01																																																						
IBD-00191	IBD-00191-SCLN-01	1	1457228	GSE1710															IBD-00191	IBD-00191-SCLN-01																																																						
IBD-00192	IBD-00192-SCLN-01	1	1457228	GSE1710															IBD-00192	IBD-00192-SCLN-01																																																						
IBD-00193	IBD-00193-SCLN-01	1	1457228	GSE1710															IBD-00193	IBD-00193-SCLN-01																																																						
IBD-00295	IBD-00295-PBMC-01	1	1457228	GSE3365															IBD-00295	IBD-00295-PBMC-01																																																						
IBD-00296	IBD-00296-PBMC-01	1	1457228	GSE3365															IBD-00296	IBD-00296-PBMC-01																																																						
IBD-00297	IBD-00297-PBMC-01	1	1457228	GSE3365															IBD-00297	IBD-00297-PBMC-01																																																						
IBD-00298	IBD-00298-PBMC-01	1	1457228	GSE3365															IBD-00298	IBD-00298-PBMC-01																																																						
IBD-00299	IBD-00299-PBMC-01	1	1457228	GSE3365															IBD-00299	IBD-00299-PBMC-01																																																						
IBD-00300	IBD-00300-PBMC-01	1	1457228	GSE3365															IBD-00300	IBD-00300-PBMC-01																																																						
IBD-00301	IBD-00301-PBMC-01	1	1457228	GSE3365															IBD-00301	IBD-00301-PBMC-01																																																						
IBD-00302	IBD-00302-CLN-01	1	1457228	E-MEXP-2083															IBD-00302	IBD-00302-CLN-01																																																						
IBD-00303	IBD-00303-PBMC-01	1	1457228	GSE3365															IBD-00303	IBD-00303-PBMC-01																																																						
IBD-00304	IBD-00304-CLN-01	1	1457228	E-MEXP-2083	Mesalamine	255222												Mesalamine	IBD-00304	IBD-00304-CLN-01						MESALAMINE		A1																																														
IBD-00305	IBD-00305-PBMC-01	1	1457228	GSE3365															IBD-00305	IBD-00305-PBMC-01																																																						
IBD-00306	IBD-00306-CLN-01	1	1457228	E-MEXP-2083															IBD-00306	IBD-00306-CLN-01																																																						
IBD-00307	IBD-00307-PBMC-01	1	1457228	GSE3365															IBD-00307	IBD-00307-PBMC-01																																																						
IBD-00309	IBD-00309-PBMC-01	1	1457228	GSE3365															IBD-00309	IBD-00309-PBMC-01																																																						
IBD-00310	IBD-00310-CLN-01	1	1457228	E-MEXP-2083	Mesalamine	255222												Mesalamine	IBD-00310	IBD-00310-CLN-01						MESALAMINE		A1																																														
IBD-00311	IBD-00311-PBMC-01	1	1457228	GSE3365															IBD-00311	IBD-00311-PBMC-01																																																						
IBD-00313	IBD-00313-PBMC-01	1	1457228	GSE3365															IBD-00313	IBD-00313-PBMC-01																																																						
IBD-00314	IBD-00314-CLN-01	1	1457228	E-MEXP-2083	Mesalamine	255222												Mesalamine	IBD-00314	IBD-00314-CLN-01						MESALAMINE		A1																																														
IBD-00315	IBD-00315-PBMC-01	1	1457228	GSE3365															IBD-00315	IBD-00315-PBMC-01																																																						
IBD-00317	IBD-00317-PBMC-01	1	1457228	GSE3365															IBD-00317	IBD-00317-PBMC-01																																																						
IBD-00319	IBD-00319-PBMC-01	1	1457228	GSE3365															IBD-00319	IBD-00319-PBMC-01																																																						
IBD-00321	IBD-00321-PBMC-01	1	1457228	GSE3365															IBD-00321	IBD-00321-PBMC-01																																																						
IBD-00322	IBD-00322-CLN-01	1	1457228	E-MEXP-2083															IBD-00322	IBD-00322-CLN-01																																																						
IBD-00323	IBD-00323-PBMC-01	1	1457228	GSE3365															IBD-00323	IBD-00323-PBMC-01																																																						
IBD-00325	IBD-00325-PBMC-01	1	1457228	GSE3365															IBD-00325	IBD-00325-PBMC-01																																																						
IBD-00326	IBD-00326-PBMC-01	1	1457228	GSE3365															IBD-00326	IBD-00326-PBMC-01																																																						
IBD-00327	IBD-00327-PBMC-01	1	1457228	GSE3365															IBD-00327	IBD-00327-PBMC-01																																																						
IBD-00328	IBD-00328-PBMC-01	1	1457228	GSE3365															IBD-00328	IBD-00328-PBMC-01																																																						
IBD-00329	IBD-00329-PBMC-01	1	1457228	GSE3365															IBD-00329	IBD-00329-PBMC-01																																																						
IBD-00330	IBD-00330-CLN-01	1	1457228	E-MTAB-184															IBD-00330	IBD-00330-CLN-01																																																						
IBD-00331	IBD-00331-PBMC-01	1	1457228	GSE3365															IBD-00331	IBD-00331-PBMC-01																																																						
IBD-00332	IBD-00332-PBMC-01	1	1457228	GSE3365															IBD-00332	IBD-00332-PBMC-01																																																						
IBD-00333	IBD-00333-PBMC-01	1	1457228	GSE3365															IBD-00333	IBD-00333-PBMC-01																																																						
IBD-00334	IBD-00334-CLN-01	1	1457228	E-MTAB-184															IBD-00334	IBD-00334-CLN-01																																																						
IBD-00337	IBD-00337-CLN-01	1	1457228	E-MTAB-184															IBD-00337	IBD-00337-CLN-01																																																						
IBD-00342	IBD-00342-CLN-01	1	1457228	E-MTAB-184															IBD-00342	IBD-00342-CLN-01																																																						
IBD-00345	IBD-00345-CLN-01	1	1457228	E-MTAB-184															IBD-00345	IBD-00345-CLN-01																																																						
IBD-00406	IBD-00406-CLN-01	1	1457228	E-MTAB-184															IBD-00406	IBD-00406-HFCLN-01																																																						
IBD-00409	IBD-00409-CLN-01	1	1457228	E-MTAB-184															IBD-00409	IBD-00409-HFCLN-01																																																						
IBD-00410	IBD-00410-CLN-01	1	1457228	E-MTAB-184															IBD-00410	IBD-00410-HFCLN-01																																																						
IBD-00411	IBD-00411-CLN-01	1	1457228	E-MTAB-184															IBD-00411	IBD-00411-HFCLN-01						MESALAMINE		B1																																														
IBD-00412	IBD-00412-CLN-01	1	1457228	E-MTAB-184															IBD-00412	IBD-00412-CLN-01																																																						
IBD-00413	IBD-00413-CLN-01	1	1457228	E-MTAB-184															IBD-00413	IBD-00413-HFCLN-01						CORTICOSTEROIDS																																																
IBD-00414	IBD-00414-CLN-01	1	1457228	E-MTAB-184															IBD-00414	IBD-00414-HFCLN-01						CORTICOSTEROIDS																																																
IBD-00415	IBD-00415-CLN-01	1	1457228	E-MTAB-184															IBD-00415	IBD-00415-HFCLN-01																																																						
IBD-00416	IBD-00416-CLN-01	1	1457228	E-MTAB-184															IBD-00416	IBD-00416-HFCLN-01						MESALAMINE																																																
IBD-00417	IBD-00417-CLN-01	1	1457228	E-MTAB-184															IBD-00417	IBD-00417-HFCLN-01						MESALAMINE																																																
IBD-00418	IBD-00418-CLN-01	1	1457228	E-MTAB-184															IBD-00418	IBD-00418-HFCLN-01																																																						
IBD-00419	IBD-00419-CLN-01	1	1457228	E-MTAB-184															IBD-00419	IBD-00419-HFCLN-01																																																						
IBD-00420	IBD-00420-CLN-01	1	1457228	E-MTAB-184															IBD-00420	IBD-00420-CLN-01																																																						
IBD-00421	IBD-00421-CLN-01	1	1457228	E-MTAB-184															IBD-00421	IBD-00421-CLN-01																																																						
IBD-00422	IBD-00422-CLN-01	1	1457228	E-MTAB-184															IBD-00422	IBD-00422-HFCLN-01						CORTICOSTEROIDS																																																
IBD-00423	IBD-00423-CLN-01	1	1457228	E-MTAB-184															IBD-00423	IBD-00423-HFCLN-01						MESALAMINE																																																
IBD-00424	IBD-00424-CLN-01	1	1457228	E-MTAB-184															IBD-00424	IBD-00424-SCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00425	IBD-00425-CLN-01	1	1457228	E-MTAB-184															IBD-00425	IBD-00425-REC-01						MESALAMINE		B1																																														
IBD-00425	IBD-00425-CLN-01	1	1457228	E-MTAB-184															IBD-00425	IBD-00425-REC-01						SULFASALAZINE		B1																																														
IBD-00425	IBD-00425-CLN-01	1	1457228	E-MTAB-184															IBD-00425	IBD-00425-REC-01						CORTICOSTEROIDS		B1																																														
IBD-00427	IBD-00427-CLN-01	1	1457228	E-MTAB-184															IBD-00427	IBD-00427-HFCLN-01																																																						
IBD-00429	IBD-00429-CLN-01	1	1457228	E-MTAB-184															IBD-00429	IBD-00429-HFCLN-01																																																						
IBD-00431	IBD-00431-CLN-01	1	1457228	E-MTAB-184															IBD-00431	IBD-00431-HFCLN-01						MESALAMINE		B1																																														
IBD-00431	IBD-00431-CLN-01	1	1457228	E-MTAB-184															IBD-00431	IBD-00431-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00434	IBD-00434-CLN-01	1	1457228	E-MTAB-184															IBD-00434	IBD-00434-CLN-01																																																						
IBD-00436	IBD-00436-CLN-01	1	1457228	E-MTAB-184															IBD-00436	IBD-00436-CLN-01																																																						
IBD-00437	IBD-00437-CLN-01	1	1457228	E-MTAB-184															IBD-00437	IBD-00437-HFCLN-01						MESALAMINE		B1																																														
IBD-00437	IBD-00437-CLN-01	1	1457228	E-MTAB-184															IBD-00437	IBD-00437-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00437	IBD-00437-CLN-01	1	1457228	E-MTAB-184															IBD-00437	IBD-00437-HFCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00438	IBD-00438-CLN-01	1	1457228	E-MTAB-184															IBD-00438	IBD-00438-HFCLN-01						MESALAMINE		B1																																														
IBD-00438	IBD-00438-CLN-01	1	1457228	E-MTAB-184															IBD-00438	IBD-00438-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00439	IBD-00439-CLN-01	1	1457228	E-MTAB-184															IBD-00439	IBD-00439-HFCLN-01						MESALAMINE		B1																																														
IBD-00439	IBD-00439-CLN-01	1	1457228	E-MTAB-184															IBD-00439	IBD-00439-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00440	IBD-00440-CLN-01	1	1457228	E-MTAB-184															IBD-00440	IBD-00440-HFCLN-01						MESALAMINE		B1																																														
IBD-00440	IBD-00440-CLN-01	1	1457228	E-MTAB-184															IBD-00440	IBD-00440-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00441	IBD-00441-CLN-01	1	1457228	E-MTAB-184															IBD-00441	IBD-00441-SCLN-01						MESALAMINE		B1																																														
IBD-00441	IBD-00441-CLN-01	1	1457228	E-MTAB-184															IBD-00441	IBD-00441-SCLN-01						SULFASALAZINE		B1																																														
IBD-00442	IBD-00442-CLN-01	1	1457228	E-MTAB-184															IBD-00442	IBD-00442-SCLN-01						MESALAMINE		B1																																														
IBD-00442	IBD-00442-CLN-01	1	1457228	E-MTAB-184															IBD-00442	IBD-00442-SCLN-01						SULFASALAZINE		B1																																														
IBD-00443	IBD-00443-CLN-01	1	1457228	E-MTAB-184															IBD-00443	IBD-00443-HFCLN-01																																																						
IBD-00444	IBD-00444-CLN-01	1	1457228	E-MTAB-184															IBD-00444	IBD-00444-HFCLN-01						MESALAMINE		B1																																														
IBD-00444	IBD-00444-CLN-01	1	1457228	E-MTAB-184															IBD-00444	IBD-00444-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00445	IBD-00445-CLN-01	1	1457228	E-MTAB-184															IBD-00445	IBD-00445-HFCLN-01						MESALAMINE		B1																																														
IBD-00445	IBD-00445-CLN-01	1	1457228	E-MTAB-184															IBD-00445	IBD-00445-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00446	IBD-00446-CLN-01	1	1457228	E-MTAB-184															IBD-00446	IBD-00446-SCLN-01						MESALAMINE		B1																																														
IBD-00446	IBD-00446-CLN-01	1	1457228	E-MTAB-184															IBD-00446	IBD-00446-SCLN-01						SULFASALAZINE		B1																																														
IBD-00446	IBD-00446-CLN-01	1	1457228	E-MTAB-184															IBD-00446	IBD-00446-SCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00447	IBD-00447-CLN-01	1	1457228	E-MTAB-184															IBD-00447	IBD-00447-CLN-01																																																						
IBD-00448	IBD-00448-CLN-01	1	1457228	E-MTAB-184															IBD-00448	IBD-00448-CLN-01																																																						
IBD-00449	IBD-00449-CLN-01	1	1457228	E-MTAB-184															IBD-00449	IBD-00449-HFCLN-01																																																						
IBD-00450	IBD-00450-CLN-01	1	1457228	E-MTAB-184															IBD-00450	IBD-00450-HFCLN-01						MESALAMINE		B1																																														
IBD-00450	IBD-00450-CLN-01	1	1457228	E-MTAB-184															IBD-00450	IBD-00450-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00451	IBD-00451-CLN-01	1	1457228	E-MTAB-184															IBD-00451	IBD-00451-HFCLN-01						MESALAMINE		B1																																														
IBD-00451	IBD-00451-CLN-01	1	1457228	E-MTAB-184															IBD-00451	IBD-00451-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00452	IBD-00452-CLN-01	1	1457228	E-MTAB-184															IBD-00452	IBD-00452-HFCLN-01						MESALAMINE		B1																																														
IBD-00452	IBD-00452-CLN-01	1	1457228	E-MTAB-184															IBD-00452	IBD-00452-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00453	IBD-00453-CLN-01	1	1457228	E-MTAB-184															IBD-00453	IBD-00453-HFCLN-01						MESALAMINE		B1																																														
IBD-00481	IBD-00481-CLN-01	1	1457228	GSE37283															IBD-00481	IBD-00481-CLN-01																																																						
IBD-00482	IBD-00482-CLN-01	1	1457228	GSE37283															IBD-00482	IBD-00482-CLN-01																																																						
IBD-00483	IBD-00483-CLN-01	1	1457228	GSE37283															IBD-00483	IBD-00483-CLN-01																																																						
IBD-00484	IBD-00484-CLN-01	1	1457228	GSE37283															IBD-00484	IBD-00484-CLN-01																																																						
IBD-00485	IBD-00485-CLN-01	1	1457228	GSE37283															IBD-00485	IBD-00485-CLN-01																																																						
IBD-00486	IBD-00486-CLN-01	1	1457228	GSE37283															IBD-00486	IBD-00486-CLN-01																																																						
IBD-00487	IBD-00487-CLN-01	1	1457228	GSE37283															IBD-00487	IBD-00487-CLN-01																																																						
IBD-00488	IBD-00488-CLN-01	1	1457228	GSE37283															IBD-00488	IBD-00488-CLN-01																																																						
IBD-00489	IBD-00489-CLN-01	1	1457228	GSE37283															IBD-00489	IBD-00489-CLN-01																																																						
IBD-00490	IBD-00490-CLN-01	1	1457228	GSE37283															IBD-00490	IBD-00490-CLN-01																																																						
IBD-00491	IBD-00491-CLN-01	1	1457228	GSE37283															IBD-00491	IBD-00491-CLN-01																																																						
IBD-00499	IBD-00499-REC-01	1	1457228	GSE3629															IBD-00499	IBD-00499-REC-01																																																						
IBD-00500	IBD-00500-REC-01	1	1457228	GSE3629															IBD-00500	IBD-00500-REC-01																																																						
IBD-00501	IBD-00501-REC-01	1	1457228	GSE3629															IBD-00501	IBD-00501-REC-01																																																						
IBD-00502	IBD-00502-REC-01	1	1457228	GSE3629															IBD-00502	IBD-00502-REC-01																																																						
IBD-00503	IBD-00503-REC-01	1	1457228	GSE3629															IBD-00503	IBD-00503-REC-01																																																						
IBD-00504	IBD-00504-REC-01	1	1457228	GSE3629															IBD-00504	IBD-00504-REC-01																																																						
IBD-00505	IBD-00505-REC-01	1	1457228	GSE3629															IBD-00505	IBD-00505-REC-01																																																						
IBD-00506	IBD-00506-REC-01	1	1457228	GSE3629															IBD-00506	IBD-00506-REC-01																																																						
IBD-00507	IBD-00507-REC-01	1	1457228	GSE3629															IBD-00507	IBD-00507-REC-01																																																						
IBD-00508	IBD-00508-REC-01	1	1457228	GSE3629															IBD-00508	IBD-00508-REC-01																																																						
IBD-00509	IBD-00509-REC-01	1	1457228	GSE3629															IBD-00509	IBD-00509-REC-01																																																						
IBD-00510	IBD-00510-REC-01	1	1457228	GSE3629															IBD-00510	IBD-00510-REC-01																																																						
IBD-00511	IBD-00511-REC-01	1	1457228	GSE3629															IBD-00511	IBD-00511-REC-01																																																						
IBD-00512	IBD-00512-REC-01	1	1457228	GSE3629															IBD-00512	IBD-00512-REC-01																																																						
IBD-00513	IBD-00513-REC-01	1	1457228	GSE3629															IBD-00513	IBD-00513-REC-01																																																						
IBD-00514	IBD-00514-REC-01	1	1457228	GSE3629															IBD-00514	IBD-00514-REC-01																																																						
IBD-00515	IBD-00515-REC-01	1	1457228	GSE3629															IBD-00515	IBD-00515-REC-01																																																						
IBD-00516	IBD-00516-REC-01	1	1457228	GSE3629															IBD-00516	IBD-00516-REC-01																																																						
IBD-00517	IBD-00517-REC-01	1	1457228	GSE3629															IBD-00517	IBD-00517-REC-01																																																						
IBD-00518	IBD-00518-REC-01	1	1457228	GSE3629															IBD-00518	IBD-00518-REC-01																																																						
IBD-00519	IBD-00519-REC-01	1	1457228	GSE3629															IBD-00519	IBD-00519-REC-01																																																						
IBD-00520	IBD-00520-REC-01	1	1457228	GSE3629															IBD-00520	IBD-00520-REC-01																																																						
IBD-00521	IBD-00521-REC-01	1	1457228	GSE3629															IBD-00521	IBD-00521-REC-01																																																						
IBD-00522	IBD-00522-REC-01	1	1457228	GSE3629															IBD-00522	IBD-00522-REC-01																																																						
IBD-00523	IBD-00523-REC-01	1	1457228	GSE3629															IBD-00523	IBD-00523-REC-01																																																						
IBD-00524	IBD-00524-REC-01	1	1457228	GSE3629															IBD-00524	IBD-00524-REC-01																																																						
IBD-00525	IBD-00525-REC-01	1	1457228	GSE3629															IBD-00525	IBD-00525-REC-01																																																						
IBD-00526	IBD-00526-REC-01	1	1457228	GSE3629															IBD-00526	IBD-00526-REC-01																																																						
IBD-00527	IBD-00527-REC-01	1	1457228	GSE3629															IBD-00527	IBD-00527-REC-01																																																						
IBD-00528	IBD-00528-REC-01	1	1457228	GSE3629															IBD-00528	IBD-00528-REC-01																																																						
IBD-00529	IBD-00529-REC-01	1	1457228	GSE3629															IBD-00529	IBD-00529-REC-01																																																						
IBD-00530	IBD-00530-REC-01	1	1457228	GSE3629															IBD-00530	IBD-00530-REC-01																																																						
IBD-00531	IBD-00531-REC-01	1	1457228	GSE3629															IBD-00531	IBD-00531-REC-01																																																						
IBD-00532	IBD-00532-REC-01	1	1457228	GSE3629															IBD-00532	IBD-00532-REC-01																																																						
IBD-00533	IBD-00533-REC-01	1	1457228	GSE3629															IBD-00533	IBD-00533-REC-01																																																						
IBD-00534	IBD-00534-REC-01	1	1457228	GSE3629															IBD-00534	IBD-00534-REC-01																																																						
IBD-00535	IBD-00535-REC-01	1	1457228	GSE3629															IBD-00535	IBD-00535-REC-01																																																						
IBD-00536	IBD-00536-REC-01	1	1457228	GSE3629															IBD-00536	IBD-00536-REC-01																																																						
IBD-00537	IBD-00537-REC-01	1	1457228	GSE3629															IBD-00537	IBD-00537-REC-01																																																						
IBD-00539	IBD-00539-REC-01	1	1457228	GSE3629															IBD-00539	IBD-00539-REC-01																																																						
IBD-00540	IBD-00540-REC-01	1	1457228	GSE3629															IBD-00540	IBD-00540-REC-01																																																						
IBD-00541	IBD-00541-REC-01	1	1457228	GSE3629															IBD-00541	IBD-00541-REC-01																																																						
IBD-00542	IBD-00542-REC-01	1	1457228	GSE3629															IBD-00542	IBD-00542-REC-01																																																						
IBD-00543	IBD-00543-REC-01	1	1457228	GSE3629															IBD-00543	IBD-00543-REC-01																																																						
IBD-00544	IBD-00544-REC-01	1	1457228	GSE3629															IBD-00544	IBD-00544-REC-01																																																						
IBD-00545	IBD-00545-REC-01	1	1457228	GSE3629															IBD-00545	IBD-00545-REC-01																																																						
IBD-00546	IBD-00546-REC-01	1	1457228	GSE3629															IBD-00546	IBD-00546-REC-01																																																						
IBD-00547	IBD-00547-REC-01	1	1457228	GSE3629															IBD-00547	IBD-00547-REC-01																																																						
IBD-00548	IBD-00548-REC-01	1	1457228	GSE3629															IBD-00548	IBD-00548-REC-01																																																						
IBD-00549	IBD-00549-REC-01	1	1457228	GSE3629															IBD-00549	IBD-00549-REC-01																																																						
IBD-00550	IBD-00550-CD4T-02	1	1457228	E-MTAB-331			Partial Response												IBD-00550	IBD-00550-CD8T-02					406 Commenced Azathioprine (2mg/kg)A (60 days).	CORTICOSTEROIDS				AZATHIOPRINE	2	mg/kg		60	Partial Response	Partial Response											INTRAVENOUS																											
IBD-00550	IBD-00550-CD4T-02	1	1457228	E-MTAB-331			Partial Response												IBD-00550	IBD-00550-CD8T-02					406 Commenced Azathioprine (2mg/kg)A (60 days).	CORTICOSTEROIDS				CYCLOSPORIN					Partial Response	Partial Response	Complete Remission	Complete Response									INTRAVENOUS																											
IBD-00551	IBD-00551-REC-01	1	1457228	GSE3629															IBD-00551	IBD-00551-REC-01																																																						
IBD-00552	IBD-00552-REC-01	1	1457228	GSE3629															IBD-00552	IBD-00552-REC-01																																																						
IBD-00553	IBD-00553-REC-01	1	1457228	GSE3629															IBD-00553	IBD-00553-REC-01																																																						
IBD-00554	IBD-00554-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	65								Corticosteroids	259627		IBD-00554	IBD-00554-PB-01	65	65													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00555	IBD-00555-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	35	30							Corticosteroids	259627		IBD-00555	IBD-00555-PB-01	35	35	30	30											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00556	IBD-00556-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	15								Corticosteroids	259627		IBD-00556	IBD-00556-PB-01	15	15													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00557	IBD-00557-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	75	45							Corticosteroids	259627		IBD-00557	IBD-00557-PB-01	75	75	45	45											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00558	IBD-00558-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	60	30							Corticosteroids	259627		IBD-00558	IBD-00558-PB-01	60	60	30	30											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00559	IBD-00559-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	55	40							Corticosteroids	259627		IBD-00559	IBD-00559-PB-01	55	55	40	40											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00560	IBD-00560-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	30								Corticosteroids	259627		IBD-00560	IBD-00560-PB-01	30	30													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00561	IBD-00561-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	65								Corticosteroids	259627		IBD-00561	IBD-00561-PB-01	65	65													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00562	IBD-00562-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	30								Corticosteroids	259627		IBD-00562	IBD-00562-PB-01	30	30													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00563	IBD-00563-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	10								Corticosteroids	259627		IBD-00563	IBD-00563-PB-01	10	10													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00564	IBD-00564-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	45								Corticosteroids	259627		IBD-00564	IBD-00564-PB-01	45	45													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00565	IBD-00565-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	45	30							Corticosteroids	259627		IBD-00565	IBD-00565-PB-01	45	45	30	30											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00566	IBD-00566-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	25								Corticosteroids	259627		IBD-00566	IBD-00566-PB-01	25	25													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00567	IBD-00567-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	10								Corticosteroids	259627		IBD-00567	IBD-00567-PB-01	10	10													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00568	IBD-00568-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	40	5							Corticosteroids	259627		IBD-00568	IBD-00568-PB-01	40	40	5	5											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00569	IBD-00569-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	35	20							Corticosteroids	259627		IBD-00569	IBD-00569-PB-01	35	35	20	20											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00570	IBD-00570-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	30								Corticosteroids	259627		IBD-00570	IBD-00570-PB-01	30	30													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00571	IBD-00571-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	50	30							Corticosteroids	259627		IBD-00571	IBD-00571-PB-01	50	50	30	30											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00572	IBD-00572-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	20								Corticosteroids	259627		IBD-00572	IBD-00572-PB-01	20	20													Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00573	IBD-00573-WB-01	1	1457228	GSE21231	Corticosteroids	259627	Yes	40	10							Corticosteroids	259627		IBD-00573	IBD-00573-PB-01	40	40	10	10											Responder	Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00574	IBD-00574-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	75	80							Corticosteroids	259627		IBD-00574	IBD-00574-PB-01	75	75	80	80											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00575	IBD-00575-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	60	65							Corticosteroids	259627		IBD-00575	IBD-00575-PB-01	60	60	65	65											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00576	IBD-00576-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	75	65							Corticosteroids	259627		IBD-00576	IBD-00576-PB-01	75	75	65	65											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00577	IBD-00577-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	50	35							Corticosteroids	259627		IBD-00577	IBD-00577-PB-01	50	50	35	35											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00578	IBD-00578-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	75	65							Corticosteroids	259627		IBD-00578	IBD-00578-PB-01	75	75	65	65											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00579	IBD-00579-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	70	70							Corticosteroids	259627		IBD-00579	IBD-00579-PB-01	70	70	70	70											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00580	IBD-00580-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	80	75							Corticosteroids	259627		IBD-00580	IBD-00580-PB-01	80	80	75	75											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00581	IBD-00581-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	80								Corticosteroids	259627		IBD-00581	IBD-00581-PB-01	80	80													Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00582	IBD-00582-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	65	75							Corticosteroids	259627		IBD-00582	IBD-00582-PB-01	65	65	75	75											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00583	IBD-00583-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	75	75							Corticosteroids	259627		IBD-00583	IBD-00583-PB-01	75	75	75	75											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00584	IBD-00584-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	70	60							Corticosteroids	259627		IBD-00584	IBD-00584-PB-01	70	70	60	60											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00585	IBD-00585-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	50	30							Corticosteroids	259627		IBD-00585	IBD-00585-PB-01	50	50	30	30											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00586	IBD-00586-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	60	45							Corticosteroids	259627		IBD-00586	IBD-00586-PB-01	60	60	45	45											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00587	IBD-00587-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	80	50							Corticosteroids	259627		IBD-00587	IBD-00587-PB-01	80	80	50	50											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00588	IBD-00588-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	50								Corticosteroids	259627		IBD-00588	IBD-00588-PB-01	50	50													Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00589	IBD-00589-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	55								Corticosteroids	259627		IBD-00589	IBD-00589-PB-01	55	55													Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00590	IBD-00590-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	45	50							Corticosteroids	259627		IBD-00590	IBD-00590-PB-01	45	45	50	50											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00591	IBD-00591-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	70	70							Corticosteroids	259627		IBD-00591	IBD-00591-PB-01	70	70	70	70											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00592	IBD-00592-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	45	45							Corticosteroids	259627		IBD-00592	IBD-00592-PB-01	45	45	45	45											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00593	IBD-00593-WB-01	1	1457228	GSE21231	Corticosteroids	259627	No	85	80							Corticosteroids	259627		IBD-00593	IBD-00593-PB-01	85	85	80	80											Non-Responder	No Response			K1		MULTIPLE				NO REQUIREMENT FOR SECOND LINE MEDICAL INTERVENTION OR SURGERY BY DISCHARGE	PUCAI SCORE LESS THAN OR EQUAL TO 45 POINTS BY DAY 5 OF THERAPY																METHYLPREDNISOLONE	Y				INTRAVENOUS	K1						
IBD-00595	IBD-00595-SCLN-01	1	1457228	GSE22619	Corticosteroids	259627										Corticosteroids	259627		IBD-00595	IBD-00595-SCLN-01						CORTICOSTEROIDS			N1																																													
IBD-00595	IBD-00595-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00595	IBD-00595-SCLN-01						MESALAMINE			N1																																													
IBD-00597	IBD-00597-SCLN-01	1	1457228	GSE22619	Azathioprine	256898								Azathioprine	256898				IBD-00597	IBD-00597-SCLN-01						AZATHIOPRINE			N1																																													
IBD-00597	IBD-00597-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00597	IBD-00597-SCLN-01						MESALAMINE			N1																																													
IBD-00599	IBD-00599-SCLN-01	1	1457228	GSE22619	Corticosteroids	259627										Corticosteroids	259627		IBD-00599	IBD-00599-SCLN-01						CORTICOSTEROIDS			N1																																													
IBD-00599	IBD-00599-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00599	IBD-00599-SCLN-01						MESALAMINE			N1																																													
IBD-00601	IBD-00601-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00601	IBD-00601-SCLN-01						MESALAMINE			N1																																													
IBD-00603	IBD-00603-SCLN-01	1	1457228	GSE22619															IBD-00603	IBD-00603-ILM-01																																																						
IBD-00605	IBD-00605-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00605	IBD-00605-SCLN-01						MESALAMINE			N1																																													
IBD-00607	IBD-00607-SCLN-01	1	1457228	GSE22619	Azathioprine	256898								Azathioprine	256898				IBD-00607	IBD-00607-SCLN-01						AZATHIOPRINE			N1																																													
IBD-00607	IBD-00607-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00607	IBD-00607-SCLN-01						MESALAMINE			N1																																													
IBD-00609	IBD-00609-SCLN-01	1	1457228	GSE22619	Corticosteroids	259627										Corticosteroids	259627		IBD-00609	IBD-00609-SCLN-01						CORTICOSTEROIDS			N1																																													
IBD-00609	IBD-00609-SCLN-01	1	1457228	GSE22619	Mesalamine	255222												Mesalamine	IBD-00609	IBD-00609-SCLN-01						MESALAMINE			N1																																													
IBD-00610	IBD-00610-DCLN-01	1	1457228	GSE13367															IBD-00610	IBD-00610-DCLN-01																																																						
IBD-00618	IBD-00618-DCLN-01	1	1457228	GSE13367															IBD-00610	IBD-00610-DCLN-02																																																						
IBD-00611	IBD-00611-DCLN-01	1	1457228	GSE13367															IBD-00611	IBD-00611-DCLN-01																																																						
IBD-00619	IBD-00619-DCLN-01	1	1457228	GSE13367															IBD-00611	IBD-00611-DCLN-02																																																						
IBD-00612	IBD-00612-DCLN-01	1	1457228	GSE13367															IBD-00612	IBD-00612-DCLN-01																																																						
IBD-00620	IBD-00620-DCLN-01	1	1457228	GSE13367															IBD-00612	IBD-00612-DCLN-02																																																						
IBD-00613	IBD-00613-DCLN-01	1	1457228	GSE13367															IBD-00613	IBD-00613-DCLN-01																																																						
IBD-00621	IBD-00621-DCLN-01	1	1457228	GSE13367															IBD-00613	IBD-00613-DCLN-02																																																						
IBD-00614	IBD-00614-DCLN-01	1	1457228	GSE13367															IBD-00614	IBD-00614-DCLN-01																																																						
IBD-00622	IBD-00622-DCLN-01	1	1457228	GSE13367															IBD-00614	IBD-00614-DCLN-02																																																						
IBD-00615	IBD-00615-DCLN-01	1	1457228	GSE13367															IBD-00615	IBD-00615-DCLN-01																																																						
IBD-00624	IBD-00624-DCLN-01	1	1457228	GSE13367															IBD-00615	IBD-00615-DCLN-02																																																						
IBD-00616	IBD-00616-DCLN-01	1	1457228	GSE13367															IBD-00616	IBD-00616-DCLN-01																																																						
IBD-00626	IBD-00626-DCLN-01	1	1457228	GSE13367															IBD-00616	IBD-00616-DCLN-02																																																						
IBD-00617	IBD-00617-DCLN-01	1	1457228	GSE13367															IBD-00617	IBD-00617-DCLN-01																																																						
IBD-00628	IBD-00628-DCLN-01	1	1457228	GSE13367															IBD-00617	IBD-00617-DCLN-02																																																						
IBD-00630	IBD-00630-DCLN-01	1	1457228	GSE13367															IBD-00630	IBD-00630-DCLN-01																																																						
IBD-00645	IBD-00645-DCLN-01	1	1457228	GSE13367															IBD-00630	IBD-00630-DCLN-02																																																						
IBD-00632	IBD-00632-DCLN-01	1	1457228	GSE13367															IBD-00632	IBD-00632-DCLN-01																																																						
IBD-00647	IBD-00647-DCLN-01	1	1457228	GSE13367															IBD-00632	IBD-00632-DCLN-02																																																						
IBD-00633	IBD-00633-DCLN-01	1	1457228	GSE13367															IBD-00633	IBD-00633-DCLN-01																																																						
IBD-00649	IBD-00649-DCLN-01	1	1457228	GSE13367															IBD-00633	IBD-00633-DCLN-02																																																						
IBD-00635	IBD-00635-DCLN-01	1	1457228	GSE13367															IBD-00635	IBD-00635-DCLN-01																																																						
IBD-00651	IBD-00651-DCLN-01	1	1457228	GSE13367															IBD-00635	IBD-00635-DCLN-02																																																						
IBD-00636	IBD-00636-DCLN-01	1	1457228	GSE13367															IBD-00636	IBD-00636-DCLN-01																																																						
IBD-00653	IBD-00653-DCLN-01	1	1457228	GSE13367															IBD-00636	IBD-00636-DCLN-02																																																						
IBD-00638	IBD-00638-DCLN-01	1	1457228	GSE13367															IBD-00638	IBD-00638-DCLN-01																																																						
IBD-00655	IBD-00655-DCLN-01	1	1457228	GSE13367															IBD-00638	IBD-00638-DCLN-02																																																						
IBD-00639	IBD-00639-DCLN-01	1	1457228	GSE13367															IBD-00639	IBD-00639-DCLN-01																																																						
IBD-00657	IBD-00657-DCLN-01	1	1457228	GSE13367															IBD-00639	IBD-00639-DCLN-02																																																						
IBD-00641	IBD-00641-DCLN-01	1	1457228	GSE13367															IBD-00641	IBD-00641-DCLN-01																																																						
IBD-00658	IBD-00658-DCLN-01	1	1457228	GSE13367															IBD-00641	IBD-00641-DCLN-02																																																						
IBD-00643	IBD-00643-DCLN-01	1	1457228	GSE13367															IBD-00643	IBD-00643-DCLN-01																																																						
IBD-00660	IBD-00660-DCLN-01	1	1457228	GSE13367															IBD-00643	IBD-00643-DCLN-02																																																						
IBD-00672	IBD-00672-CLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00672	IBD-00672-CLN-01						MESALAMINE			Y1																																													
IBD-00672	IBD-00672-CLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00672	IBD-00672-CLN-01						MESALAMINE			Y1																																													
IBD-00674	IBD-00674-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00674	IBD-00674-DCLN-01						MESALAMINE			Y1																																													
IBD-00676	IBD-00676-DCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00676	IBD-00676-DCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00678	IBD-00678-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00678	IBD-00678-DCLN-01						MESALAMINE			Y1																																													
IBD-00680	IBD-00680-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00680	IBD-00680-DCLN-01						MESALAMINE			Y1																																													
IBD-00682	IBD-00682-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00682	IBD-00682-DCLN-01						MESALAMINE			Y1																																													
IBD-00684	IBD-00684-DCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00684	IBD-00684-DCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00686	IBD-00686-DCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00686	IBD-00686-DCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00688	IBD-00688-DCLN-01	1	1457228	GSE9452															IBD-00688	IBD-00688-DCLN-01																																																						
IBD-00690	IBD-00690-DCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00690	IBD-00690-DCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00692	IBD-00692-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00692	IBD-00692-DCLN-01						MESALAMINE			Y1																																													
IBD-00694	IBD-00694-DCLN-01	1	1457228	GSE9452															IBD-00694	IBD-00694-DCLN-01																																																						
IBD-00695	IBD-00695-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00695	IBD-00695-DCLN-01						MESALAMINE			Y1																																													
IBD-00697	IBD-00697-DCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00697	IBD-00697-DCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00698	IBD-00698-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00698	IBD-00698-DCLN-01						MESALAMINE			Y1																																													
IBD-00700	IBD-00700-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00700	IBD-00700-DCLN-01						MESALAMINE			Y1																																													
IBD-00701	IBD-00701-DCLN-01	1	1457228	GSE9452															IBD-00701	IBD-00701-DCLN-01																																																						
IBD-00703	IBD-00703-DCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00703	IBD-00703-DCLN-01						MESALAMINE			Y1																																													
IBD-00705	IBD-00705-SCLN-01	1	1457228	GSE9452															IBD-00705	IBD-00705-SCLN-01																																																						
IBD-00707	IBD-00707-SCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00707	IBD-00707-SCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00707	IBD-00707-SCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00707	IBD-00707-SCLN-01						MESALAMINE			Y1																																													
IBD-00709	IBD-00709-SCLN-01	1	1457228	GSE9452	Corticosteroids	259627										Corticosteroids	259627		IBD-00709	IBD-00709-SCLN-01						CORTICOSTEROIDS			Y1																		SYSTEMIC																											
IBD-00709	IBD-00709-SCLN-01	1	1457228	GSE9452	Mesalamine	255222												Mesalamine	IBD-00709	IBD-00709-SCLN-01						MESALAMINE			Y1																																													
IBD-00710	IBD-00710-ACLN-01	1	1457228	GSE10616															IBD-00710	IBD-00710-ACLN-01																																																						
IBD-00711	IBD-00711-ACLN-01	1	1457228	GSE10616															IBD-00711	IBD-00711-ACLN-01																																																						
IBD-00713	IBD-00713-ACLN-01	1	1457228	GSE10616															IBD-00713	IBD-00713-ACLN-01																																																						
IBD-00714	IBD-00714-ACLN-01	1	1457228	GSE10616															IBD-00714	IBD-00714-ACLN-01																																																						
IBD-00715	IBD-00715-ACLN-01	1	1457228	GSE10616															IBD-00715	IBD-00715-ACLN-01																																																						
IBD-00717	IBD-00717-ACLN-01	1	1457228	GSE10616															IBD-00717	IBD-00717-ACLN-01																																																						
IBD-00718	IBD-00718-ACLN-01	1	1457228	GSE10616															IBD-00718	IBD-00718-ACLN-01																																																						
IBD-00719	IBD-00719-ACLN-01	1	1457228	GSE10616															IBD-00719	IBD-00719-ACLN-01																																																						
IBD-00721	IBD-00721-ACLN-01	1	1457228	GSE10616															IBD-00721	IBD-00721-ACLN-01																																																						
IBD-00722	IBD-00722-ACLN-01	1	1457228	GSE10616															IBD-00722	IBD-00722-ACLN-01																																																						
IBD-00830	IBD-00830-CLN-01	1	1457228	GSE2461															IBD-00830	IBD-00830-CLN-01																																																						
IBD-00834	IBD-00834-CLN-01	1	1457228	GSE2461															IBD-00834	IBD-00834-CLN-01																																																						
IBD-00859	IBD-00859-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00859	IBD-00859-CLN-01																			P1	Q1										GSM578715	P2/10mg/kg/W0 (36359)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00859	IBD-00859-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00859	IBD-00859-CLN-02																			P1	Q1										GSM578716	P2/10mg/kg/W8 (36360)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00859	IBD-00859-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00859	IBD-00859-CLN-03																			P1	Q1										GSM578717	P2/10mg/kg/W30 (36361)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00859	IBD-00859-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00859	IBD-00859-CLN-03																			P1	Q1										GSM578717	P2/10mg/kg/W30 (36361)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00859	IBD-00859-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00859	IBD-00859-CLN-03																			P1	Q1										GSM578717	P2/10mg/kg/W30 (36361)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00860	IBD-00860-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00860	IBD-00860-CLN-01																			P1	Q1										GSM578720	P4/10mg/kg/W0 (36364)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00860	IBD-00860-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00860	IBD-00860-CLN-02																			P1	Q1										GSM578721	P4/10mg/kg/W8 (36365)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00860	IBD-00860-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00860	IBD-00860-CLN-02																			P1	Q1										GSM578721	P4/10mg/kg/W8 (36365)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00860	IBD-00860-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00860	IBD-00860-CLN-02																			P1	Q1										GSM578721	P4/10mg/kg/W8 (36365)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00861	IBD-00861-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00861	IBD-00861-CLN-01																			P1	Q1										GSM578722	P5/10mg/kg/W0 (36366)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00861	IBD-00861-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00861	IBD-00861-CLN-02																			P1	Q1										GSM578723	P5/10mg/kg/W30 (36367)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00861	IBD-00861-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00861	IBD-00861-CLN-02																			P1	Q1										GSM578723	P5/10mg/kg/W30 (36367)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00861	IBD-00861-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00861	IBD-00861-CLN-02																			P1	Q1										GSM578723	P5/10mg/kg/W30 (36367)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00862	IBD-00862-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00862	IBD-00862-CLN-01																			P1	Q1										GSM578734	P10/10mg/kg/W0 (36379)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00862	IBD-00862-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00862	IBD-00862-CLN-02																			P1	Q1										GSM578735	P10/10mg/kg/W8 (36380)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00862	IBD-00862-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00862	IBD-00862-CLN-03																			P1	Q1										GSM578736	P10/10mg/kg/W30 (36381)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00862	IBD-00862-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00862	IBD-00862-CLN-03																			P1	Q1										GSM578736	P10/10mg/kg/W30 (36381)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00862	IBD-00862-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00862	IBD-00862-CLN-03																			P1	Q1										GSM578736	P10/10mg/kg/W30 (36381)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00863	IBD-00863-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00863	IBD-00863-CLN-01																			P1	Q1										GSM578737	P11/10mg/kg/W0 (36382)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00863	IBD-00863-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00863	IBD-00863-CLN-02																			P1	Q1										GSM578738	P11/10mg/kg/W8 (36383)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00863	IBD-00863-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00863	IBD-00863-CLN-02																			P1	Q1										GSM578738	P11/10mg/kg/W8 (36383)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00863	IBD-00863-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00863	IBD-00863-CLN-02																			P1	Q1										GSM578738	P11/10mg/kg/W8 (36383)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00864	IBD-00864-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00864	IBD-00864-CLN-01																			P1	Q1										GSM578745	P15/10mg/kg/W0 (36415)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00864	IBD-00864-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00864	IBD-00864-CLN-02																			P1	Q1										GSM578746	P15/10mg/kg/W8 (36416)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00864	IBD-00864-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00864	IBD-00864-CLN-03																			P1	Q1										GSM578747	P15/10mg/kg/W30 (36417)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00864	IBD-00864-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00864	IBD-00864-CLN-03																			P1	Q1										GSM578747	P15/10mg/kg/W30 (36417)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00864	IBD-00864-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00864	IBD-00864-CLN-03																			P1	Q1										GSM578747	P15/10mg/kg/W30 (36417)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00865	IBD-00865-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00865	IBD-00865-CLN-01																			P1	Q1										GSM578751	P17/10mg/kg/W0 (36423)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00865	IBD-00865-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00865	IBD-00865-CLN-02																			P1	Q1										GSM578752	P17/10mg/kg/W8 (36424)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00865	IBD-00865-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00865	IBD-00865-CLN-03																			P1	Q1										GSM578753	P17/10mg/kg/W30 (36425)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00865	IBD-00865-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00865	IBD-00865-CLN-03																			P1	Q1										GSM578753	P17/10mg/kg/W30 (36425)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00865	IBD-00865-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00865	IBD-00865-CLN-03																			P1	Q1										GSM578753	P17/10mg/kg/W30 (36425)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00866	IBD-00866-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00866	IBD-00866-CLN-01																			P1	Q1										GSM578757	P19/10mg/kg/W0 (36430)				No Clinical Response	No Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00866	IBD-00866-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00866	IBD-00866-CLN-02																			P1	Q1										GSM578758	P19/10mg/kg/W8 (36431)				No Clinical Response	No Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00866	IBD-00866-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00866	IBD-00866-CLN-03																			P1	Q1										GSM578759	P19/10mg/kg/W30 (36432)				No Clinical Response	No Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00866	IBD-00866-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00866	IBD-00866-CLN-03																			P1	Q1										GSM578759	P19/10mg/kg/W30 (36432)				No Clinical Response	No Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00866	IBD-00866-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	Yes	Infliximab	487061						IBD-00866	IBD-00866-CLN-03																			P1	Q1										GSM578759	P19/10mg/kg/W30 (36432)				No Clinical Response	No Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00867	IBD-00867-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00867	IBD-00867-CLN-01																			P1	Q1										GSM578762	P21/10mg/kg/W0 (36435)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00867	IBD-00867-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00867	IBD-00867-CLN-03																			P1	Q1										GSM578763	P21/10mg/kg/W30 (36436)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00867	IBD-00867-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00867	IBD-00867-CLN-03																			P1	Q1										GSM578763	P21/10mg/kg/W30 (36436)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00867	IBD-00867-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00867	IBD-00867-CLN-03																			P1	Q1										GSM578763	P21/10mg/kg/W30 (36436)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00868	IBD-00868-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00868	IBD-00868-CLN-01																			P1	Q1										GSM578764	P22/10mg/kg/W0 (36437)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00868	IBD-00868-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00868	IBD-00868-CLN-03																			P1	Q1										GSM578765	P22/10mg/kg/W30 (36438)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00868	IBD-00868-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00868	IBD-00868-CLN-03																			P1	Q1										GSM578765	P22/10mg/kg/W30 (36438)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00868	IBD-00868-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00868	IBD-00868-CLN-03																			P1	Q1										GSM578765	P22/10mg/kg/W30 (36438)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00869	IBD-00869-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00869	IBD-00869-CLN-01																			P1	Q1										GSM578768	P24/10mg/kg/W0 (36441)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00869	IBD-00869-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00869	IBD-00869-CLN-02																			P1	Q1										GSM578769	P24/10mg/kg/W8 (36442)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00869	IBD-00869-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00869	IBD-00869-CLN-03																			P1	Q1										GSM578770	P24/10mg/kg/W30 (36443)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
				GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00869	IBD-00869-CLN-03																			P1	Q1										GSM578770	P24/10mg/kg/W30 (36443)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
				GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00869	IBD-00869-CLN-03																			P1	Q1										GSM578770	P24/10mg/kg/W30 (36443)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00870	IBD-00870-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00870	IBD-00870-CLN-01																			P1	Q1										GSM578776	P27/10mg/kg/W0 (36450)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00870	IBD-00870-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00870	IBD-00870-CLN-02																			P1	Q1										GSM578777	P27/10mg/kg/W8 (36451)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00870	IBD-00870-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00870	IBD-00870-CLN-03																			P1	Q1										GSM578778	P27/10mg/kg/W30 (36452)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00870	IBD-00870-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00870	IBD-00870-CLN-03																			P1	Q1										GSM578778	P27/10mg/kg/W30 (36452)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00870	IBD-00870-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00870	IBD-00870-CLN-03																			P1	Q1										GSM578778	P27/10mg/kg/W30 (36452)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00871	IBD-00871-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00871	IBD-00871-CLN-01																			P1	Q1										GSM578779	P28/10mg/kg/W0 (36453)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00871	IBD-00871-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00871	IBD-00871-CLN-02																			P1	Q1										GSM578780	P28/10mg/kg/W8 (36454)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00871	IBD-00871-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00871	IBD-00871-CLN-03																			P1	Q1										GSM578781	P28/10mg/kg/W30 (36455)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00871	IBD-00871-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00871	IBD-00871-CLN-03																			P1	Q1										GSM578781	P28/10mg/kg/W30 (36455)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00871	IBD-00871-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00871	IBD-00871-CLN-03																			P1	Q1										GSM578781	P28/10mg/kg/W30 (36455)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00872	IBD-00872-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00872	IBD-00872-CLN-01																			P1	Q1										GSM578788	P32/10mg/kg/W0 (36462)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00872	IBD-00872-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00872	IBD-00872-CLN-02																			P1	Q1										GSM578789	P32/10mg/kg/W8 (36463)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00872	IBD-00872-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00872	IBD-00872-CLN-02																			P1	Q1										GSM578789	P32/10mg/kg/W8 (36463)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00872	IBD-00872-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00872	IBD-00872-CLN-02																			P1	Q1										GSM578789	P32/10mg/kg/W8 (36463)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00873	IBD-00873-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00873	IBD-00873-CLN-01																			P1	Q1										GSM578792	P34/10mg/kg/W0 (36466)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00873	IBD-00873-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00873	IBD-00873-CLN-02																			P1	Q1										GSM578793	P34/10mg/kg/W8 (36467)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00873	IBD-00873-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00873	IBD-00873-CLN-03																			P1	Q1										GSM578794	P34/10mg/kg/W30 (36468)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00873	IBD-00873-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00873	IBD-00873-CLN-03																			P1	Q1										GSM578794	P34/10mg/kg/W30 (36468)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00873	IBD-00873-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00873	IBD-00873-CLN-03																			P1	Q1										GSM578794	P34/10mg/kg/W30 (36468)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00874	IBD-00874-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00874	IBD-00874-CLN-01																			P1	Q1										GSM578797	P36/10mg/kg/W0 (36471)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00874	IBD-00874-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00874	IBD-00874-CLN-02																			P1	Q1										GSM578798	P36/10mg/kg/W8 (36472)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00874	IBD-00874-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00874	IBD-00874-CLN-03																			P1	Q1										GSM578799	P36/10mg/kg/W30 (36473)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00874	IBD-00874-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00874	IBD-00874-CLN-03																			P1	Q1										GSM578799	P36/10mg/kg/W30 (36473)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00874	IBD-00874-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00874	IBD-00874-CLN-03																			P1	Q1										GSM578799	P36/10mg/kg/W30 (36473)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00875	IBD-00875-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00875	IBD-00875-CLN-01																			P1	Q1										GSM578807	P41/10mg/kg/W0 (36502)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00875	IBD-00875-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00875	IBD-00875-CLN-02																			P1	Q1										GSM578808	P41/10mg/kg/W8 (36503)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00875	IBD-00875-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00875	IBD-00875-CLN-02																			P1	Q1										GSM578808	P41/10mg/kg/W8 (36503)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00875	IBD-00875-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00875	IBD-00875-CLN-02																			P1	Q1										GSM578808	P41/10mg/kg/W8 (36503)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	10	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00876	IBD-00876-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00876	IBD-00876-CLN-01																			P1	Q1										GSM578713	P1/5mg/kg/W0 (36357)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00876	IBD-00876-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00876	IBD-00876-CLN-02																			P1	Q1										GSM578714	P1/5mg/kg/W8 (36358)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00876	IBD-00876-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00876	IBD-00876-CLN-02																			P1	Q1										GSM578714	P1/5mg/kg/W8 (36358)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00876	IBD-00876-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00876	IBD-00876-CLN-02																			P1	Q1										GSM578714	P1/5mg/kg/W8 (36358)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00877	IBD-00877-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00877	IBD-00877-CLN-01																			P1	Q1										GSM578718	P3/5mg/kg/W0 (36362)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00877	IBD-00877-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00877	IBD-00877-CLN-02																			P1	Q1										GSM578719	P3/5mg/kg/W8 (36363)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00877	IBD-00877-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00877	IBD-00877-CLN-02																			P1	Q1										GSM578719	P3/5mg/kg/W8 (36363)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00877	IBD-00877-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00877	IBD-00877-CLN-02																			P1	Q1										GSM578719	P3/5mg/kg/W8 (36363)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00878	IBD-00878-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00878	IBD-00878-CLN-01																			P1	Q1										GSM578731	P9/5mg/kg/W0 (36376)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00878	IBD-00878-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00878	IBD-00878-CLN-02																			P1	Q1										GSM578732	P9/5mg/kg/W8 (36377)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00878	IBD-00878-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00878	IBD-00878-CLN-03																			P1	Q1										GSM578733	P9/5mg/kg/W30 (36378)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00878	IBD-00878-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00878	IBD-00878-CLN-03																			P1	Q1										GSM578733	P9/5mg/kg/W30 (36378)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00878	IBD-00878-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00878	IBD-00878-CLN-03																			P1	Q1										GSM578733	P9/5mg/kg/W30 (36378)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00879	IBD-00879-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00879	IBD-00879-CLN-01																			P1	Q1										GSM578740|GSM578741	P13/5mg/kg/W0				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00879	IBD-00879-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00879	IBD-00879-CLN-02																			P1	Q1										GSM578742	P13/5mg/kg/W8 (36387)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00879	IBD-00879-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00879	IBD-00879-CLN-02																			P1	Q1										GSM578742	P13/5mg/kg/W8 (36387)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00879	IBD-00879-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00879	IBD-00879-CLN-02																			P1	Q1										GSM578742	P13/5mg/kg/W8 (36387)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00880	IBD-00880-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00880	IBD-00880-CLN-01																			P1	Q1										GSM578743	P14/5mg/kg/W0 (36413)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00880	IBD-00880-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00880	IBD-00880-CLN-02																			P1	Q1										GSM578744	P14/5mg/kg/W8 (36414)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00880	IBD-00880-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00880	IBD-00880-CLN-02																			P1	Q1										GSM578744	P14/5mg/kg/W8 (36414)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00880	IBD-00880-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00880	IBD-00880-CLN-02																			P1	Q1										GSM578744	P14/5mg/kg/W8 (36414)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00881	IBD-00881-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00881	IBD-00881-CLN-01																			P1	Q1										GSM578748	P16/5mg/kg/W0 (36419)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00881	IBD-00881-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00881	IBD-00881-CLN-02																			P1	Q1										GSM578749	P16/5mg/kg/W8 (36420)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00881	IBD-00881-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00881	IBD-00881-CLN-03																			P1	Q1										GSM578750	P16/5mg/kg/W30 (36421)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00881	IBD-00881-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00881	IBD-00881-CLN-03																			P1	Q1										GSM578750	P16/5mg/kg/W30 (36421)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00881	IBD-00881-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00881	IBD-00881-CLN-03																			P1	Q1										GSM578750	P16/5mg/kg/W30 (36421)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00882	IBD-00882-CLN-01	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00882	IBD-00882-CLN-01																			P1	Q1										GSM578782	P29/5mg/kg/W0 (36456)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00882	IBD-00882-CLN-02	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00882	IBD-00882-CLN-02																			P1	Q1										GSM578783	P29/5mg/kg/W8 (36457)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00882	IBD-00882-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00882	IBD-00882-CLN-03																			P1	Q1										GSM578784	P29/5mg/kg/W30 (36458)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00882	IBD-00882-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00882	IBD-00882-CLN-03																			P1	Q1										GSM578784	P29/5mg/kg/W30 (36458)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00882	IBD-00882-CLN-03	1	1457228	GSE23597	Infliximab	487061				No	No	Infliximab	487061						IBD-00882	IBD-00882-CLN-03																			P1	Q1										GSM578784	P29/5mg/kg/W30 (36458)				No Clinical Response	No Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00883	IBD-00883-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00883	IBD-00883-CLN-01																			P1	Q1										GSM578790	P33/5mg/kg/W0 (36464)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00883	IBD-00883-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00883	IBD-00883-CLN-02																			P1	Q1										GSM578791	P33/5mg/kg/W8 (36465)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00883	IBD-00883-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00883	IBD-00883-CLN-02																			P1	Q1										GSM578791	P33/5mg/kg/W8 (36465)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00883	IBD-00883-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00883	IBD-00883-CLN-02																			P1	Q1										GSM578791	P33/5mg/kg/W8 (36465)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00884	IBD-00884-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00884	IBD-00884-CLN-01																			P1	Q1										GSM578800	P38/5mg/kg/W0 (36493)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00884	IBD-00884-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00884	IBD-00884-CLN-02																			P1	Q1										GSM578801	P38/5mg/kg/W8 (36494)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00884	IBD-00884-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00884	IBD-00884-CLN-03																			P1	Q1										GSM578802	P38/5mg/kg/W30 (36495)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00884	IBD-00884-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00884	IBD-00884-CLN-03																			P1	Q1										GSM578802	P38/5mg/kg/W30 (36495)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00884	IBD-00884-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00884	IBD-00884-CLN-03																			P1	Q1										GSM578802	P38/5mg/kg/W30 (36495)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00885	IBD-00885-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00885	IBD-00885-CLN-01																			P1	Q1										GSM578804	P40/5mg/kg/W0 (36499)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00885	IBD-00885-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00885	IBD-00885-CLN-02																			P1	Q1										GSM578805	P40/5mg/kg/W8 (36500)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00885	IBD-00885-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00885	IBD-00885-CLN-03																			P1	Q1										GSM578806	P40/5mg/kg/W30 (36501)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00885	IBD-00885-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00885	IBD-00885-CLN-03																			P1	Q1										GSM578806	P40/5mg/kg/W30 (36501)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00885	IBD-00885-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00885	IBD-00885-CLN-03																			P1	Q1										GSM578806	P40/5mg/kg/W30 (36501)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00886	IBD-00886-CLN-01	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00886	IBD-00886-CLN-01																			P1	Q1										GSM578815	P45/5mg/kg/W0 (36511)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00886	IBD-00886-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00886	IBD-00886-CLN-02																			P1	Q1										GSM578816	P45/5mg/kg/W8 (36512)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00886	IBD-00886-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00886	IBD-00886-CLN-03																			P1	Q1										GSM578817	P45/5mg/kg/W30 (36513)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00886	IBD-00886-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00886	IBD-00886-CLN-03																			P1	Q1										GSM578817	P45/5mg/kg/W30 (36513)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00886	IBD-00886-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00886	IBD-00886-CLN-03																			P1	Q1										GSM578817	P45/5mg/kg/W30 (36513)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00887	IBD-00887-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00887	IBD-00887-CLN-02																			P1	Q1										GSM578766	P23/5mg/kg/W8 (36439)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00887	IBD-00887-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00887	IBD-00887-CLN-03																			P1	Q1										GSM578767	P23/5mg/kg/W30 (36440)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00887	IBD-00887-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00887	IBD-00887-CLN-03																			P1	Q1										GSM578767	P23/5mg/kg/W30 (36440)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00887	IBD-00887-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00887	IBD-00887-CLN-03																			P1	Q1										GSM578767	P23/5mg/kg/W30 (36440)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00887	IBD-00887-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	No	Infliximab	487061						IBD-00887	IBD-00887-CLN-03																			P1	Q1										GSM578767	P23/5mg/kg/W30 (36440)				Clinical Response	Response	No Clinical Response	No Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00888	IBD-00888-CLN-02	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00888	IBD-00888-CLN-02																			P1	Q1										GSM578809	P42/5mg/kg/W8 (36504)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00888	IBD-00888-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00888	IBD-00888-CLN-03																			P1	Q1										GSM578810	P42/5mg/kg/W30 (36505)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					211
IBD-00888	IBD-00888-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00888	IBD-00888-CLN-03																			P1	Q1										GSM578810	P42/5mg/kg/W30 (36505)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					1
IBD-00888	IBD-00888-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00888	IBD-00888-CLN-03																			P1	Q1										GSM578810	P42/5mg/kg/W30 (36505)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	P1	Q1					15
IBD-00888	IBD-00888-CLN-03	1	1457228	GSE23597	Infliximab	487061				Yes	Yes	Infliximab	487061						IBD-00888	IBD-00888-CLN-03																			P1	Q1										GSM578810	P42/5mg/kg/W30 (36505)				Clinical Response	Response	Clinical Response	Response	MULTIPLE	DECREASE IN THE TOTAL MAYO SCORE OF AT LEAST THREE POINTS AND AT LEAST 30%	DECREASE IN THE MAYO SCORE'S SUBSCORE FOR RECTAL BLEEDING OF AT LEAST ONE POINT OR AN ABSOLUTE SUBSCORE FOR RECTAL BLEEDING OF 0 OR 1	INFLIXIMAB	Y	5	mg/kg	EVERY 8 WEEKS	INTRAVENOUS	P1	Q1					43
IBD-00889	IBD-00889-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00889	IBD-00889-CLN-01																														GSM578724	P6/Placebo/W0 (36368)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00889	IBD-00889-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00889	IBD-00889-CLN-02																														GSM578725	P6/Placebo/W8 (36369)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00889	IBD-00889-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00889	IBD-00889-CLN-03																														GSM578726	P6/Placebo/W30 (36370)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00889	IBD-00889-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00889	IBD-00889-CLN-03																														GSM578726	P6/Placebo/W30 (36370)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00889	IBD-00889-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00889	IBD-00889-CLN-03																														GSM578726	P6/Placebo/W30 (36370)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00890	IBD-00890-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00890	IBD-00890-CLN-01																														GSM578727	P7/Placebo/W0 (36371)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00890	IBD-00890-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00890	IBD-00890-CLN-02																														GSM578728	P7/Placebo/W8 (36372)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00890	IBD-00890-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00890	IBD-00890-CLN-02																														GSM578728	P7/Placebo/W8 (36372)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00890	IBD-00890-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00890	IBD-00890-CLN-02																														GSM578728	P7/Placebo/W8 (36372)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00891	IBD-00891-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00891	IBD-00891-CLN-01																														GSM578729	P8/Placebo/W0 (36373)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00891	IBD-00891-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00891	IBD-00891-CLN-02																														GSM578730	P8/Placebo/W8 (36374)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00891	IBD-00891-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00891	IBD-00891-CLN-02																														GSM578730	P8/Placebo/W8 (36374)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00891	IBD-00891-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00891	IBD-00891-CLN-02																														GSM578730	P8/Placebo/W8 (36374)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00892	IBD-00892-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00892	IBD-00892-CLN-01																														GSM578754	P18/Placebo/W0 (36426)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00892	IBD-00892-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00892	IBD-00892-CLN-02																														GSM578755	P18/Placebo/W8 (36427)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00892	IBD-00892-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00892	IBD-00892-CLN-03																														GSM578756	P18/Placebo/W30 (36429)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00892	IBD-00892-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00892	IBD-00892-CLN-03																														GSM578756	P18/Placebo/W30 (36429)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00892	IBD-00892-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00892	IBD-00892-CLN-03																														GSM578756	P18/Placebo/W30 (36429)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00893	IBD-00893-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00893	IBD-00893-CLN-01																														GSM578760	P20/Placebo/W0 (36433)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00893	IBD-00893-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00893	IBD-00893-CLN-03																														GSM578761	P20/Placebo/W30 (36434)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00893	IBD-00893-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00893	IBD-00893-CLN-03																														GSM578761	P20/Placebo/W30 (36434)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00893	IBD-00893-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00893	IBD-00893-CLN-03																														GSM578761	P20/Placebo/W30 (36434)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00894	IBD-00894-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00894	IBD-00894-CLN-01																														GSM578771	P25/Placebo/W0 (36444)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00894	IBD-00894-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00894	IBD-00894-CLN-02																														GSM578772	P25/Placebo/W8 (36445)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00894	IBD-00894-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00894	IBD-00894-CLN-03																														GSM578773	P25/Placebo/W30 (36446)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00894	IBD-00894-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00894	IBD-00894-CLN-03																														GSM578773	P25/Placebo/W30 (36446)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00894	IBD-00894-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00894	IBD-00894-CLN-03																														GSM578773	P25/Placebo/W30 (36446)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00895	IBD-00895-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00895	IBD-00895-CLN-01																														GSM578774	P26/Placebo/W0 (36447)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00895	IBD-00895-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00895	IBD-00895-CLN-03																														GSM578775	P26/Placebo/W30 (36448)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00895	IBD-00895-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00895	IBD-00895-CLN-03																														GSM578775	P26/Placebo/W30 (36448)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00895	IBD-00895-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00895	IBD-00895-CLN-03																														GSM578775	P26/Placebo/W30 (36448)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00896	IBD-00896-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00896	IBD-00896-CLN-01																														GSM578785	P30/Placebo/W0 (36459)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00896	IBD-00896-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00896	IBD-00896-CLN-03																														GSM578786	P30/Placebo/W30 (36460)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00896	IBD-00896-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00896	IBD-00896-CLN-03																														GSM578786	P30/Placebo/W30 (36460)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00896	IBD-00896-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00896	IBD-00896-CLN-03																														GSM578786	P30/Placebo/W30 (36460)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00897	IBD-00897-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00897	IBD-00897-CLN-01																														GSM578795	P35/Placebo/W0 (36469)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00897	IBD-00897-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00897	IBD-00897-CLN-03																														GSM578796	P35/Placebo/W30 (36470)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00897	IBD-00897-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00897	IBD-00897-CLN-03																														GSM578796	P35/Placebo/W30 (36470)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00897	IBD-00897-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00897	IBD-00897-CLN-03																														GSM578796	P35/Placebo/W30 (36470)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00898	IBD-00898-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00898	IBD-00898-CLN-01																														GSM578812	P44/Placebo/W0 (36508)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00898	IBD-00898-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00898	IBD-00898-CLN-02																														GSM578813	P44/Placebo/W8 (36509)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00898	IBD-00898-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00898	IBD-00898-CLN-03																														GSM578814	P44/Placebo/W30 (36510)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00898	IBD-00898-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00898	IBD-00898-CLN-03																														GSM578814	P44/Placebo/W30 (36510)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00898	IBD-00898-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00898	IBD-00898-CLN-03																														GSM578814	P44/Placebo/W30 (36510)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00899	IBD-00899-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00899	IBD-00899-CLN-01																														GSM578818	P46/Placebo/W0 (36514)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00899	IBD-00899-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00899	IBD-00899-CLN-02																														GSM578819	P46/Placebo/W8 (36515)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00899	IBD-00899-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00899	IBD-00899-CLN-03																														GSM578820	P46/Placebo/W30 (36516)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00899	IBD-00899-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00899	IBD-00899-CLN-03																														GSM578820	P46/Placebo/W30 (36516)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00899	IBD-00899-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00899	IBD-00899-CLN-03																														GSM578820	P46/Placebo/W30 (36516)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00900	IBD-00900-CLN-01	1	1457228	GSE23597	Infliximab	487061													IBD-00900	IBD-00900-CLN-01																														GSM578822	P48/Placebo/W0 (36518)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00900	IBD-00900-CLN-02	1	1457228	GSE23597	Infliximab	487061													IBD-00900	IBD-00900-CLN-02																														GSM578823	P48/Placebo/W8 (36519)											PLACEBO		0	mg/kg		INTRAVENOUS							1
IBD-00900	IBD-00900-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00900	IBD-00900-CLN-03																														GSM578824	P48/Placebo/W30 (36520)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							211
IBD-00900	IBD-00900-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00900	IBD-00900-CLN-03																														GSM578824	P48/Placebo/W30 (36520)											PLACEBO		0	mg/kg		INTRAVENOUS							15
IBD-00900	IBD-00900-CLN-03	1	1457228	GSE23597	Infliximab	487061													IBD-00900	IBD-00900-CLN-03																														GSM578824	P48/Placebo/W30 (36520)											PLACEBO		0	mg/kg	EVERY 8 WEEKS	INTRAVENOUS							43
IBD-00453	IBD-00453-CLN-01	1	1457228	E-MTAB-184															IBD-00453	IBD-00453-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00454	IBD-00454-CLN-01	1	1457228	E-MTAB-184															IBD-00454	IBD-00454-CLN-01																																																						
IBD-00455	IBD-00455-CLN-01	1	1457228	E-MTAB-184															IBD-00455	IBD-00455-HFCLN-01																																																						
IBD-00456	IBD-00456-CLN-01	1	1457228	E-MTAB-184															IBD-00456	IBD-00456-HFCLN-01						MESALAMINE		B1																																														
IBD-00456	IBD-00456-CLN-01	1	1457228	E-MTAB-184															IBD-00456	IBD-00456-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00908	IBD-00908-CLN-01	1	1457228	E-MTAB-184															IBD-00908	IBD-00908-CLN-01																																																						
IBD-00908	IBD-00908-CLN-02	1	1457228	E-MTAB-184															IBD-00908	IBD-00908-CEC-02																																																						
IBD-00909	IBD-00909-CLN-01	1	1457228	E-MTAB-184															IBD-00909	IBD-00909-HFCLN-01						MESALAMINE																																																
IBD-00909	IBD-00909-CLN-02	1	1457228	E-MTAB-184															IBD-00909	IBD-00909-SCLN-02						SULFASALAZINE																																																
IBD-00910	IBD-00910-CLN-01	1	1457228	E-MTAB-184															IBD-00910	IBD-00910-HFCLN-01						MESALAMINE																																																
IBD-00910	IBD-00910-CLN-02	1	1457228	E-MTAB-184															IBD-00910	IBD-00910-CLN-02						SULFASALAZINE																																																
IBD-00457	IBD-00457-CLN-01	1	1457228	E-MTAB-184															IBD-00457	IBD-00457-CLN-01																																																						
IBD-00458	IBD-00458-CLN-01	1	1457228	E-MTAB-184															IBD-00458	IBD-00458-SCLN-01						MESALAMINE		B1																																														
IBD-00912	IBD-00912-CLN-01	1	1457228	E-MTAB-184															IBD-00912	IBD-00912-HFCLN-01						CORTICOSTEROIDS																																																
IBD-00912	IBD-00912-CLN-02	1	1457228	E-MTAB-184															IBD-00912	IBD-00912-DCLN-02						CORTICOSTEROIDS																																																
IBD-00913	IBD-00913-CLN-01	1	1457228	E-MTAB-184															IBD-00913	IBD-00913-HFCLN-01						CORTICOSTEROIDS																																																
IBD-00913	IBD-00913-CLN-02	1	1457228	E-MTAB-184															IBD-00913	IBD-00913-CLN-02						CORTICOSTEROIDS																																																
IBD-00914	IBD-00914-CLN-01	1	1457228	E-MTAB-184															IBD-00914	IBD-00914-HFCLN-01																																																						
IBD-00914	IBD-00914-CLN-02	1	1457228	E-MTAB-184															IBD-00914	IBD-00914-CLN-02																																																						
IBD-00458	IBD-00458-CLN-01	1	1457228	E-MTAB-184															IBD-00458	IBD-00458-SCLN-01						SULFASALAZINE		B1																																														
IBD-00458	IBD-00458-CLN-01	1	1457228	E-MTAB-184															IBD-00458	IBD-00458-SCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00916	IBD-00916-CLN-01	1	1457228	E-MTAB-184															IBD-00916	IBD-00916-HFCLN-01																																																						
IBD-00916	IBD-00916-CLN-02	1	1457228	E-MTAB-184															IBD-00916	IBD-00916-REC-02																																																						
IBD-00917	IBD-00917-CLN-01	1	1457228	E-MTAB-184															IBD-00917	IBD-00917-HFCLN-01						MESALAMINE																																																
IBD-00917	IBD-00917-CLN-02	1	1457228	E-MTAB-184															IBD-00917	IBD-00917-CLN-02						SULFASALAZINE																																																
IBD-00918	IBD-00918-CLN-01	1	1457228	E-MTAB-184															IBD-00918	IBD-00918-CLN-01																																																						
IBD-00918	IBD-00918-CLN-02	1	1457228	E-MTAB-184															IBD-00918	IBD-00918-TCLN-02																																																						
IBD-00460	IBD-00460-CLN-01	1	1457228	E-MTAB-184															IBD-00460	IBD-00460-SCLN-01						MESALAMINE		B1																																														
IBD-00460	IBD-00460-CLN-01	1	1457228	E-MTAB-184															IBD-00460	IBD-00460-SCLN-01						SULFASALAZINE		B1																																														
IBD-00460	IBD-00460-CLN-01	1	1457228	E-MTAB-184															IBD-00460	IBD-00460-SCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00461	IBD-00461-CLN-01	1	1457228	E-MTAB-184															IBD-00461	IBD-00461-REC-01						MESALAMINE		B1																																														
IBD-00921	IBD-00921-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00921	IBD-00921-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00921	IBD-00921-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00921	IBD-00921-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00922	IBD-00922-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00922	IBD-00922-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00922	IBD-00922-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00922	IBD-00922-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00461	IBD-00461-CLN-01	1	1457228	E-MTAB-184															IBD-00461	IBD-00461-REC-01						SULFASALAZINE		B1																																														
IBD-00462	IBD-00462-CLN-01	1	1457228	E-MTAB-184															IBD-00462	IBD-00462-HFCLN-01																																																						
IBD-00924	IBD-00924-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00924	IBD-00924-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00924	IBD-00924-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00924	IBD-00924-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00925	IBD-00925-CLN-01	1	1457228	E-MTAB-184															IBD-00925	IBD-00925-CLN-01						MESALAMINE																																																
IBD-00925	IBD-00925-CLN-02	1	1457228	E-MTAB-184															IBD-00925	IBD-00925-SCLN-02						SULFASALAZINE																																																
IBD-00926	IBD-00926-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00926	IBD-00926-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00926	IBD-00926-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00926	IBD-00926-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00927	IBD-00927-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00927	IBD-00927-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00927	IBD-00927-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00927	IBD-00927-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00928	IBD-00928-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00928	IBD-00928-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00928	IBD-00928-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00928	IBD-00928-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00929	IBD-00929-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00929	IBD-00929-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00929	IBD-00929-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00929	IBD-00929-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00930	IBD-00930-CLN-01	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00930	IBD-00930-CLN-01															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00930	IBD-00930-CLN-02	1	1457228	GSE16879	Infliximab	487061	Yes					Infliximab	487061						IBD-00930	IBD-00930-CLN-02															Responder	Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00463	IBD-00463-CLN-01	1	1457228	E-MTAB-184															IBD-00463	IBD-00463-DCLN-01						MESALAMINE		B1																																														
IBD-00463	IBD-00463-CLN-01	1	1457228	E-MTAB-184															IBD-00463	IBD-00463-DCLN-01						SULFASALAZINE		B1																																														
IBD-00932	IBD-00932-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00932	IBD-00932-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00932	IBD-00932-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00932	IBD-00932-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00933	IBD-00933-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00933	IBD-00933-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00933	IBD-00933-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00933	IBD-00933-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00463	IBD-00463-CLN-01	1	1457228	E-MTAB-184															IBD-00463	IBD-00463-DCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00464	IBD-00464-CLN-01	1	1457228	E-MTAB-184															IBD-00464	IBD-00464-REC-01																																																						
IBD-00935	IBD-00935-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00935	IBD-00935-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00935	IBD-00935-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00935	IBD-00935-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00936	IBD-00936-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00936	IBD-00936-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00936	IBD-00936-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00936	IBD-00936-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00937	IBD-00937-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00937	IBD-00937-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00937	IBD-00937-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00937	IBD-00937-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00938	IBD-00938-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00938	IBD-00938-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00938	IBD-00938-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00938	IBD-00938-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00939	IBD-00939-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00939	IBD-00939-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00939	IBD-00939-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00939	IBD-00939-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00940	IBD-00940-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00940	IBD-00940-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00940	IBD-00940-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00940	IBD-00940-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00941	IBD-00941-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00941	IBD-00941-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00941	IBD-00941-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00941	IBD-00941-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00942	IBD-00942-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00942	IBD-00942-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00942	IBD-00942-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00942	IBD-00942-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00465	IBD-00465-CLN-01	1	1457228	E-MTAB-184															IBD-00465	IBD-00465-HFCLN-01						MESALAMINE		B1																																														
IBD-00465	IBD-00465-CLN-01	1	1457228	E-MTAB-184															IBD-00465	IBD-00465-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00944	IBD-00944-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00944	IBD-00944-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00944	IBD-00944-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00944	IBD-00944-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00945	IBD-00945-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00945	IBD-00945-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00945	IBD-00945-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00945	IBD-00945-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00946	IBD-00946-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00946	IBD-00946-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00946	IBD-00946-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00946	IBD-00946-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00947	IBD-00947-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00947	IBD-00947-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00947	IBD-00947-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00947	IBD-00947-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00948	IBD-00948-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00948	IBD-00948-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00948	IBD-00948-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00948	IBD-00948-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00949	IBD-00949-CLN-01	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00949	IBD-00949-CLN-01															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00949	IBD-00949-CLN-02	1	1457228	GSE16879	Infliximab	487061	No					Infliximab	487061						IBD-00949	IBD-00949-CLN-02															Non-Responder	No Response			G1		MULTIPLE	DECREASE TO A MAYO ENDOSCOPIC SUBSCORE OF 0 OR 1	DECREASE TO GRADE 0 OR 1 ON THE HISTOLOGICAL SCORE	COMPLETE MUCOSAL HEALING																		INFLIXIMAB	Y	5	mg/kg		INTRAVENOUS	G1		2	0-1 WEEK	P0W/P1W	BEFORE TREATMENT	
IBD-00466	IBD-00466-CLN-01	1	1457228	E-MTAB-184															IBD-00466	IBD-00466-REC-01						MESALAMINE		B1																																														
IBD-00466	IBD-00466-CLN-01	1	1457228	E-MTAB-184															IBD-00466	IBD-00466-REC-01						SULFASALAZINE		B1																																														
IBD-00951	IBD-00951-CLN-01	1	1457228	E-MTAB-184															IBD-00951	IBD-00951-HFCLN-01																																																						
IBD-00951	IBD-00951-CLN-02	1	1457228	E-MTAB-184															IBD-00951	IBD-00951-SCLN-02																																																						
IBD-00466	IBD-00466-CLN-01	1	1457228	E-MTAB-184															IBD-00466	IBD-00466-REC-01						CORTICOSTEROIDS		B1																																														
IBD-00467	IBD-00467-CLN-01	1	1457228	E-MTAB-184															IBD-00467	IBD-00467-HFCLN-01																																																						
IBD-00468	IBD-00468-CLN-01	1	1457228	E-MTAB-184															IBD-00468	IBD-00468-HFCLN-01																																																						
IBD-00470	IBD-00470-CLN-01	1	1457228	E-MTAB-184															IBD-00470	IBD-00470-REC-01						MESALAMINE		B1																																														
IBD-00470	IBD-00470-CLN-01	1	1457228	E-MTAB-184															IBD-00470	IBD-00470-REC-01						SULFASALAZINE		B1																																														
IBD-00472	IBD-00472-CLN-01	1	1457228	E-MTAB-184															IBD-00472	IBD-00472-HFCLN-01						MESALAMINE		B1																																														
IBD-00472	IBD-00472-CLN-01	1	1457228	E-MTAB-184															IBD-00472	IBD-00472-HFCLN-01						SULFASALAZINE		B1																																														
IBD-00476	IBD-00476-CLN-01	1	1457228	E-MTAB-184															IBD-00476	IBD-00476-REC-01						MESALAMINE		B1																																														
IBD-00476	IBD-00476-CLN-01	1	1457228	E-MTAB-184															IBD-00476	IBD-00476-REC-01						SULFASALAZINE		B1																																														
IBD-00904	IBD-00904-CLN-01	1	1457228	E-MTAB-184															IBD-00904	IBD-00904-CLN-01																																																						
IBD-00905	IBD-00905-CLN-01	1	1457228	E-MTAB-184															IBD-00905	IBD-00905-CLN-01																																																						
IBD-00905	IBD-00905-CLN-02	1	1457228	E-MTAB-184															IBD-00905	IBD-00905-CLN-02																																																						
IBD-00906	IBD-00906-CLN-01	1	1457228	E-MTAB-184															IBD-00906	IBD-00906-CLN-01																																																						
IBD-00906	IBD-00906-CLN-02	1	1457228	E-MTAB-184															IBD-00906	IBD-00906-CLN-02																																																						
IBD-00911	IBD-00911-CLN-01	1	1457228	E-MTAB-184															IBD-00911	IBD-00911-CLN-01																																																						
IBD-00911	IBD-00911-CLN-02	1	1457228	E-MTAB-184															IBD-00911	IBD-00911-CLN-02																																																						
IBD-00915	IBD-00915-CLN-01	1	1457228	E-MTAB-184															IBD-00915	IBD-00915-CLN-01																																																						
IBD-00915	IBD-00915-CLN-02	1	1457228	E-MTAB-184															IBD-00915	IBD-00915-CLN-02																																																						
IBD-00919	IBD-00919-CLN-01	1	1457228	E-MTAB-184															IBD-00919	IBD-00919-CLN-01																																																						
IBD-00919	IBD-00919-CLN-02	1	1457228	E-MTAB-184															IBD-00919	IBD-00919-CLN-02																																																						
IBD-00920	IBD-00920-CLN-01	1	1457228	E-MTAB-184															IBD-00920	IBD-00920-CLN-01																																																						
IBD-00920	IBD-00920-CLN-02	1	1457228	E-MTAB-184															IBD-00920	IBD-00920-SCLN-02																																																						
IBD-00923	IBD-00923-CLN-01	1	1457228	E-MTAB-184															IBD-00923	IBD-00923-HFCLN-01						MESALAMINE		B1																																														
IBD-00923	IBD-00923-CLN-02	1	1457228	E-MTAB-184															IBD-00923	IBD-00923-CLN-02						SULFASALAZINE		B1																																														
IBD-00931	IBD-00931-CLN-01	1	1457228	E-MTAB-184															IBD-00931	IBD-00931-HFCLN-01						MESALAMINE		B1																																														
IBD-00931	IBD-00931-CLN-02	1	1457228	E-MTAB-184															IBD-00931	IBD-00931-SCLN-02						SULFASALAZINE		B1																																														
IBD-00934	IBD-00934-CLN-01	1	1457228	E-MTAB-184															IBD-00934	IBD-00934-TCLN-01						MESALAMINE		B1																																														
IBD-00934	IBD-00934-CLN-02	1	1457228	E-MTAB-184															IBD-00934	IBD-00934-ACLN-02						SULFASALAZINE		B1																																														
IBD-00943	IBD-00943-CLN-01	1	1457228	E-MTAB-184															IBD-00943	IBD-00943-HFCLN-01						MESALAMINE		B1																																														
IBD-00943	IBD-00943-CLN-02	1	1457228	E-MTAB-184															IBD-00943	IBD-00943-CLN-02						SULFASALAZINE		B1																																														
IBD-00950	IBD-00950-CLN-01	1	1457228	E-MTAB-184															IBD-00950	IBD-00950-SCLN-01																																																						
IBD-00950	IBD-00950-CLN-02	1	1457228	E-MTAB-184															IBD-00950	IBD-00950-SCLN-02																																																						
IBD-00952	IBD-00952-CLN-01	1	1457228	E-MTAB-184															IBD-00952	IBD-00952-HFCLN-01						MESALAMINE		B1																																														
IBD-00952	IBD-00952-CLN-02	1	1457228	E-MTAB-184															IBD-00952	IBD-00952-SCLN-02						SULFASALAZINE		B1																																														
IBD-00952	IBD-00952-CLN-02	1	1457228	E-MTAB-184															IBD-00952	IBD-00952-SCLN-02						CORTICOSTEROIDS		B1																																														
IBD-00953	IBD-00953-CLN-01	1	1457228	E-MTAB-184															IBD-00953	IBD-00953-CLN-01						MESALAMINE		B1																																														
IBD-00953	IBD-00953-CLN-02	1	1457228	E-MTAB-184															IBD-00953	IBD-00953-REC-02						SULFASALAZINE		B1																																														
IBD-00954	IBD-00954-CLN-01	1	1457228	E-MTAB-184															IBD-00954	IBD-00954-HFCLN-01						MESALAMINE		B1																																														
IBD-00954	IBD-00954-CLN-02	1	1457228	E-MTAB-184															IBD-00954	IBD-00954-CLN-02						SULFASALAZINE		B1																																														
IBD-00954	IBD-00954-CLN-02	1	1457228	E-MTAB-184															IBD-00954	IBD-00954-CLN-02						CORTICOSTEROIDS		B1																																														
IBD-00955	IBD-00955-CLN-01	1	1457228	E-MTAB-184															IBD-00955	IBD-00955-HFCLN-01																																																						
IBD-00955	IBD-00955-CLN-02	1	1457228	E-MTAB-184															IBD-00955	IBD-00955-CLN-02																																																						
IBD-00956	IBD-00956-CLN-01	1	1457228	E-MTAB-184															IBD-00956	IBD-00956-CLN-01						MESALAMINE		B1																																														
IBD-00956	IBD-00956-CLN-02	1	1457228	E-MTAB-184															IBD-00956	IBD-00956-SCLN-02						SULFASALAZINE		B1																																														
IBD-00957	IBD-00957-CLN-01	1	1457228	E-MTAB-184															IBD-00957	IBD-00957-HFCLN-01						MESALAMINE		B1																																														
IBD-00957	IBD-00957-CLN-02	1	1457228	E-MTAB-184															IBD-00957	IBD-00957-TCLN-02						SULFASALAZINE		B1																																														
IBD-01028	IBD-01028-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01028	IBD-01028-CD4T-01					449	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01028	IBD-01028-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01028	IBD-01028-CD8T-02					449	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01028	IBD-01028-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01028	IBD-01028-PBMC-03					449	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01030	IBD-01030-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01030	IBD-01030-CD4T-01					466	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01030	IBD-01030-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01030	IBD-01030-CD8T-02					466	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01030	IBD-01030-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01030	IBD-01030-PBMC-03					466	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01031	IBD-01031-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01031	IBD-01031-CD4T-01					468 Flare (78 days). SCCAI 12 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				PREDNISOLONE				78	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01031	IBD-01031-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01031	IBD-01031-CD8T-02					468 Flare (78 days). SCCAI 12 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		78	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01031	IBD-01031-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01031	IBD-01031-PBMC-03					468 Flare (78 days). SCCAI 12 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		78	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01033	IBD-01033-CD4T-01	1	1457228	E-MTAB-331			No Response												IBD-01033	IBD-01033-CD4T-01					418 No response|Complete remission with intravenous steroids|Flare (43 days). SCCAI 7 - Treated with increased Prednisolone dose and commenced MethotrexateA. Fully responded.	PREDNISOLONE				CORTICOSTEROIDS					No Response	No Response	Complete Remission	Complete Response										INTRAVENOUS																										
IBD-01033	IBD-01033-CD4T-02	1	1457228	E-MTAB-331			No Response												IBD-01033	IBD-01033-CD8T-02					418 No response|Complete remission with intravenous steroids|Flare (43 days). SCCAI 7 - Treated with increased Prednisolone dose and commenced MethotrexateA. Fully responded.	PREDNISOLONE				PREDNISOLONE				43	No Response	No Response	Fully Responded	Complete Response																																				
IBD-01033	IBD-01033-PBMC-03	1	1457228	E-MTAB-331			No Response												IBD-01033	IBD-01033-PBMC-03					418 No response|Complete remission with intravenous steroids|Flare (43 days). SCCAI 7 - Treated with increased Prednisolone dose and commenced MethotrexateA. Fully responded.	PREDNISOLONE				METHOTREXATE				43	No Response	No Response	Fully Responded	Complete Response																																				
IBD-01034	IBD-01034-CD4T-01	1	1457228	E-MTAB-331			Partial Response												IBD-01034	IBD-01034-CD4T-01					464 Commenced Azathioprine (2mg/kg)A (55 days).	PREDNISOLONE				CYCLOSPORIN					Partial Response	Partial Response	Complete Remission	Complete Response																																				
IBD-01034	IBD-01034-CD4T-02	1	1457228	E-MTAB-331			Partial Response												IBD-01034	IBD-01034-CD8T-02					464 Commenced Azathioprine (2mg/kg)A (55 days).	PREDNISOLONE				CORTICOSTEROIDS					Partial Response	Partial Response	Partial Response	Partial Response										INTRAVENOUS																										
IBD-01034	IBD-01034-PBMC-03	1	1457228	E-MTAB-331			Partial Response												IBD-01034	IBD-01034-PBMC-03					464 Commenced Azathioprine (2mg/kg)A (55 days).	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		55	Partial Response	Partial Response																																						
IBD-01036	IBD-01036-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01036	IBD-01036-CD4T-01					443	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01036	IBD-01036-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01036	IBD-01036-CD8T-02					443	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01036	IBD-01036-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01036	IBD-01036-PBMC-03					443	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01037	IBD-01037-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01037	IBD-01037-CD4T-01					417	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01037	IBD-01037-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01037	IBD-01037-CD8T-02					417	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01037	IBD-01037-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01037	IBD-01037-PBMC-03					417	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01039	IBD-01039-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01039	IBD-01039-CD4T-01					425 Flare (64 days). SCCAI 9 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded. Flare (238 days). SCCAI 10. - Treated with Prednisolone. Azathioprine increased (2.5mg/kg). Fully responded.	PREDNISOLONE				PREDNISOLONE				64	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01039	IBD-01039-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01039	IBD-01039-CD8T-02					425 Flare (64 days). SCCAI 9 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded. Flare (238 days). SCCAI 10. - Treated with Prednisolone. Azathioprine increased (2.5mg/kg). Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		64	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01039	IBD-01039-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01039	IBD-01039-PBMC-03					425 Flare (64 days). SCCAI 9 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded. Flare (238 days). SCCAI 10. - Treated with Prednisolone. Azathioprine increased (2.5mg/kg). Fully responded.	PREDNISOLONE				AZATHIOPRINE	2.5	mg/kg		238	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01040	IBD-01040-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01040	IBD-01040-CD4T-01					403 Flare (212 days). SCCAI 11- Treated with Prednisolone and commenced on Azathioprine (2mg/kg). Chronic continuous symptoms. Flare (463)- Treated with Prednisolone and switched to Methotrexate. Fully responded.	PREDNISOLONE				PREDNISOLONE				212	Complete Remission	Complete Response																																						
IBD-01040	IBD-01040-CD4T-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01040	IBD-01040-PBMC-03					403 Flare (212 days). SCCAI 11- Treated with Prednisolone and commenced on Azathioprine (2mg/kg). Chronic continuous symptoms. Flare (463)- Treated with Prednisolone and switched to Methotrexate. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		212	Complete Remission	Complete Response																																						
IBD-01040	IBD-01040-PBMC-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01040	IBD-01040-CD8T-02					403 Flare (212 days). SCCAI 11- Treated with Prednisolone and commenced on Azathioprine (2mg/kg). Chronic continuous symptoms. Flare (463)- Treated with Prednisolone and switched to Methotrexate. Fully responded.	PREDNISOLONE				PREDNISOLONE				463	Complete Remission	Complete Response																																						
IBD-01040	IBD-01040-PBMC-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01040	IBD-01040-CD8T-02					403 Flare (212 days). SCCAI 11- Treated with Prednisolone and commenced on Azathioprine (2mg/kg). Chronic continuous symptoms. Flare (463)- Treated with Prednisolone and switched to Methotrexate. Fully responded.	PREDNISOLONE				METHOTREXATE				463	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01042	IBD-01042-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01042	IBD-01042-CD4T-01					445	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01042	IBD-01042-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01042	IBD-01042-CD8T-02					445	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01042	IBD-01042-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01042	IBD-01042-PBMC-03					445	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01043	IBD-01043-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01043	IBD-01043-CD4T-01					456	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01043	IBD-01043-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01043	IBD-01043-CD8T-02					456	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01045	IBD-01045-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01045	IBD-01045-CD4T-01					460	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01045	IBD-01045-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01045	IBD-01045-CD8T-02					460	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01045	IBD-01045-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01045	IBD-01045-PBMC-03					460	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01047	IBD-01047-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01047	IBD-01047-CD4T-01					423	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01047	IBD-01047-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01047	IBD-01047-CD8T-02					423	6-MERCAPTOPURINE									Complete Remission	Complete Response																																						
IBD-01047	IBD-01047-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01047	IBD-01047-PBMC-03					423	6-MERCAPTOPURINE									Complete Remission	Complete Response																																						
IBD-01048	IBD-01048-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01048	IBD-01048-CD4T-01					461	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01048	IBD-01048-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01048	IBD-01048-CD8T-02					461	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01048	IBD-01048-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01048	IBD-01048-PBMC-03					461	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01050	IBD-01050-CD4T-01	1	1457228	E-MTAB-331			Partial Remission												IBD-01050	IBD-01050-CD4T-01					436 Flare (403 days). SCCAI 12 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				PREDNISOLONE				403	Partial Remission	Partial Response	Fully Responded	Complete Response																																				
IBD-01050	IBD-01050-CD4T-02	1	1457228	E-MTAB-331			Partial Remission												IBD-01050	IBD-01050-CD8T-02					436 Flare (403 days). SCCAI 12 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		403	Partial Remission	Partial Response	Fully Responded	Complete Response																																				
IBD-01050	IBD-01050-PBMC-03	1	1457228	E-MTAB-331			Partial Remission												IBD-01050	IBD-01050-PBMC-03					436 Flare (403 days). SCCAI 12 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		403	Partial Remission	Partial Response	Fully Responded	Complete Response																																				
IBD-01051	IBD-01051-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01051	IBD-01051-CD4T-01					426	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01051	IBD-01051-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01051	IBD-01051-CD8T-02					426	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01051	IBD-01051-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01051	IBD-01051-PBMC-03					426	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01053	IBD-01053-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01053	IBD-01053-CD4T-01					439 Flare (127 days). SCCAI 7 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				PREDNISOLONE				127	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01053	IBD-01053-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01053	IBD-01053-CD8T-02					439 Flare (127 days). SCCAI 7 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				PREDNISOLONE				127	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01053	IBD-01053-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01053	IBD-01053-PBMC-03					439 Flare (127 days). SCCAI 7 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		127	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01054	IBD-01054-CD4T-01	1	1457228	E-MTAB-331			Partial Response												IBD-01054	IBD-01054-CD4T-01					424. Partial response|Complete remission with Prednisolone	BUDESONIDE				PREDNISOLONE					Partial Response	Partial Response	Complete Remission	Complete Response																																				
IBD-01054	IBD-01054-CD4T-02	1	1457228	E-MTAB-331			Partial Response												IBD-01054	IBD-01054-CD8T-02					424. Partial response|Complete remission with Prednisolone	BUDESONIDE				PREDNISOLONE					Partial Response	Partial Response	Complete Remission	Complete Response																																				
IBD-01054	IBD-01054-PBMC-03	1	1457228	E-MTAB-331			Partial Response												IBD-01054	IBD-01054-PBMC-03					424. Partial response|Complete remission with Prednisolone	BUDESONIDE				PREDNISOLONE					Partial Response	Partial Response	Complete Remission	Complete Response																																				
IBD-01056	IBD-01056-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01056	IBD-01056-CD4T-01					433 Flare (373 days). SCCAI 8 - Treated with Prednisolone and commenced 6-Mercaptopurine (1mg/kg)A. Fully responded.	MESALAMINE				PREDNISOLONE				373	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01056	IBD-01056-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01056	IBD-01056-CD8T-02					433 Flare (373 days). SCCAI 8 - Treated with Prednisolone and commenced 6-Mercaptopurine (1mg/kg)A. Fully responded.	MESALAMINE				PREDNISOLONE				373	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01056	IBD-01056-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01056	IBD-01056-PBMC-03					433 Flare (373 days). SCCAI 8 - Treated with Prednisolone and commenced 6-Mercaptopurine (1mg/kg)A. Fully responded.	MESALAMINE				6-MERCAPTOPURINE	1	mg/kg		373	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01057	IBD-01057-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01057	IBD-01057-CD4T-01					462	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01057	IBD-01057-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01057	IBD-01057-CD8T-02					462	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01057	IBD-01057-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01057	IBD-01057-PBMC-03					462	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01059	IBD-01059-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01059	IBD-01059-CD4T-01					410 Flare (124 days). SCCAI 8 - Failed to respond to Prednisolone. Completely responded to Acetarsol suppositories.   Offered Azathioprine but declined  elected to use cyclical AcetarsolA. Flare (404 days). SCCAI 12- Treated with Prednisolone and Acetarsol suppositories. Fully responded.    commenced MethotrexateA.	TOPICAL THERAPY				PREDNISOLONE				124	Complete Remission	Complete Response	Failed to Respond	No Response																																				
IBD-01059	IBD-01059-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01059	IBD-01059-CD8T-02					410 Flare (124 days). SCCAI 8 - Failed to respond to Prednisolone. Completely responded to Acetarsol suppositories.   Offered Azathioprine but declined  elected to use cyclical AcetarsolA. Flare (404 days). SCCAI 12- Treated with Prednisolone and Acetarsol suppositories. Fully responded.    commenced MethotrexateA.	TOPICAL THERAPY				ACETARSOL				124	Complete Remission	Complete Response	Completely Responded	Complete Response											SUPPOSITORY																									
IBD-01059	IBD-01059-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01059	IBD-01059-PBMC-03					410 Flare (124 days). SCCAI 8 - Failed to respond to Prednisolone. Completely responded to Acetarsol suppositories.   Offered Azathioprine but declined  elected to use cyclical AcetarsolA. Flare (404 days). SCCAI 12- Treated with Prednisolone and Acetarsol suppositories. Fully responded.    commenced MethotrexateA.	TOPICAL THERAPY				PREDNISOLONE				404	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01059	IBD-01059-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01059	IBD-01059-PBMC-03					410 Flare (124 days). SCCAI 8 - Failed to respond to Prednisolone. Completely responded to Acetarsol suppositories.   Offered Azathioprine but declined  elected to use cyclical AcetarsolA. Flare (404 days). SCCAI 12- Treated with Prednisolone and Acetarsol suppositories. Fully responded.    commenced MethotrexateA.	TOPICAL THERAPY				ACETARSOL				404	Complete Remission	Complete Response	Fully Responded	Complete Response											SUPPOSITORY																									
IBD-01059	IBD-01059-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01059	IBD-01059-PBMC-03					410 Flare (124 days). SCCAI 8 - Failed to respond to Prednisolone. Completely responded to Acetarsol suppositories.   Offered Azathioprine but declined  elected to use cyclical AcetarsolA. Flare (404 days). SCCAI 12- Treated with Prednisolone and Acetarsol suppositories. Fully responded.    commenced MethotrexateA.	TOPICAL THERAPY				METHOTREXATE				404	Complete Remission	Complete Response																																						
IBD-01060	IBD-01060-CD4T-01	1	1457228	E-MTAB-331			Complete Response												IBD-01060	IBD-01060-CD4T-01					472 Flare (158). SCCAI 13 - Admitted to hospital and treated with intravenous steroids. Fully responded.   Commenced Azathioprine (2mg/kg) A	CORTICOSTEROIDS				CORTICOSTEROIDS				158	Complete Response	Complete Response	Fully Responded	Complete Response									INTRAVENOUS	INTRAVENOUS				Y	158	SEVERE ULCERATIVE COLITIS FLARE																				
IBD-01060	IBD-01060-CD4T-02	1	1457228	E-MTAB-331			Complete Response												IBD-01060	IBD-01060-CD8T-02					472 Flare (158). SCCAI 13 - Admitted to hospital and treated with intravenous steroids. Fully responded.   Commenced Azathioprine (2mg/kg) A	CORTICOSTEROIDS				AZATHIOPRINE	2	mg/kg		158	Complete Response	Complete Response											INTRAVENOUS	INTRAVENOUS				Y	158	SEVERE ULCERATIVE COLITIS FLARE																				
IBD-01060	IBD-01060-PBMC-03	1	1457228	E-MTAB-331			Complete Response												IBD-01060	IBD-01060-PBMC-03					472 Flare (158). SCCAI 13 - Admitted to hospital and treated with intravenous steroids. Fully responded.   Commenced Azathioprine (2mg/kg) A	CORTICOSTEROIDS				AZATHIOPRINE	2	mg/kg		158	Complete Response	Complete Response											INTRAVENOUS	INTRAVENOUS				Y	158	SEVERE ULCERATIVE COLITIS FLARE																				
IBD-01062	IBD-01062-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01062	IBD-01062-CD4T-01					404 Flare (96 days). SCCAI 8 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				PREDNISOLONE				96	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01062	IBD-01062-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01062	IBD-01062-CD8T-02					404 Flare (96 days). SCCAI 8 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		96	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01062	IBD-01062-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01062	IBD-01062-PBMC-03					404 Flare (96 days). SCCAI 8 - Treated with Prednisolone and commenced Azathioprine (2mg/kg)A. Fully responded.	PREDNISOLONE				AZATHIOPRINE	2	mg/kg		96	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01063	IBD-01063-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01063	IBD-01063-CD4T-01					442	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01063	IBD-01063-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01063	IBD-01063-CD8T-02					442	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01063	IBD-01063-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01063	IBD-01063-PBMC-03					442	MESALAMINE									Complete Remission	Complete Response																																						
IBD-01065	IBD-01065-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01065	IBD-01065-CD4T-01					432	BUDESONIDE									Complete Remission	Complete Response																																						
IBD-01065	IBD-01065-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01065	IBD-01065-CD8T-02					432	AZATHIOPRINE									Complete Remission	Complete Response																																						
IBD-01065	IBD-01065-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01065	IBD-01065-PBMC-03					432	AZATHIOPRINE									Complete Remission	Complete Response																																						
IBD-01066	IBD-01066-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01066	IBD-01066-CD4T-01					458	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01066	IBD-01066-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01066	IBD-01066-CD8T-02					458	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01066	IBD-01066-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01066	IBD-01066-PBMC-03					458	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01067	IBD-01067-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01067	IBD-01067-CD4T-01					413	CORTICOSTEROIDS									Complete Remission	Complete Response											INTRAVENOUS																											
IBD-01067	IBD-01067-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01067	IBD-01067-CD8T-02					413	AZATHIOPRINE									Complete Remission	Complete Response																																						
IBD-01067	IBD-01067-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01067	IBD-01067-PBMC-03					413	AZATHIOPRINE									Complete Remission	Complete Response																																						
IBD-01068	IBD-01068-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01068	IBD-01068-CD4T-01					415 Flare (212 days). SCCAI 11 - Treated with Prednisolone and commenced on 6-Mercaptopurine (1mg/kg)A. Fully responded. Flare (284 days). SCCAI 7. - Treated with high dose 5-ASA. 6-Mercaptopurine increased (1.5mg/kg). Fully responded.	PREDNISOLONE				PREDNISOLONE				212	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01068	IBD-01068-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01068	IBD-01068-CD8T-02					415 Flare (212 days). SCCAI 11 - Treated with Prednisolone and commenced on 6-Mercaptopurine (1mg/kg)A. Fully responded. Flare (284 days). SCCAI 7. - Treated with high dose 5-ASA. 6-Mercaptopurine increased (1.5mg/kg). Fully responded.	PREDNISOLONE				6-MERCAPTOPURINE	1	mg/kg		212	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01068	IBD-01068-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01068	IBD-01068-PBMC-03					415 Flare (212 days). SCCAI 11 - Treated with Prednisolone and commenced on 6-Mercaptopurine (1mg/kg)A. Fully responded. Flare (284 days). SCCAI 7. - Treated with high dose 5-ASA. 6-Mercaptopurine increased (1.5mg/kg). Fully responded.	PREDNISOLONE				MESALAMINE				284	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01068	IBD-01068-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01068	IBD-01068-PBMC-03					415 Flare (212 days). SCCAI 11 - Treated with Prednisolone and commenced on 6-Mercaptopurine (1mg/kg)A. Fully responded. Flare (284 days). SCCAI 7. - Treated with high dose 5-ASA. 6-Mercaptopurine increased (1.5mg/kg). Fully responded.	PREDNISOLONE				6-MERCAPTOPURINE	1.5	mg/kg		284	Complete Remission	Complete Response	Fully Responded	Complete Response																																				
IBD-01069	IBD-01069-CD4T-01	1	1457228	E-MTAB-331			Complete Remission												IBD-01069	IBD-01069-CD4T-01					477	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01069	IBD-01069-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01069	IBD-01069-CD8T-02					477	PREDNISOLONE									Complete Remission	Complete Response																																						
IBD-01070	IBD-01070-CD4T-01	1	1457228	E-MTAB-331			Complete Response												IBD-01070	IBD-01070-CD4T-01					427	TOPICAL THERAPY									Complete Response	Complete Response																																						
IBD-01070	IBD-01070-CD4T-02	1	1457228	E-MTAB-331			Complete Response												IBD-01070	IBD-01070-CD8T-02					427	TOPICAL THERAPY									Complete Response	Complete Response																																						
IBD-01070	IBD-01070-PBMC-03	1	1457228	E-MTAB-331			Complete Response												IBD-01070	IBD-01070-PBMC-03					427	TOPICAL THERAPY									Complete Response	Complete Response																																						
IBD-01075	IBD-01075-CD4T-02	1	1457228	E-MTAB-331			Complete Remission												IBD-01075	IBD-01075-CD8T-02					402	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01075	IBD-01075-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01075	IBD-01075-PBMC-03					402	TOPICAL THERAPY									Complete Remission	Complete Response																																						
IBD-01225	IBD-01225-WB-01	1	1457228	GSE32148															IBD-01225	IBD-01225-PBLE-01																																																						
IBD-01226	IBD-01226-WB-01	1	1457228	GSE32148															IBD-01226	IBD-01226-PBLE-01																																																						
IBD-01227	IBD-01227-WB-01	1	1457228	GSE32148															IBD-01227	IBD-01227-PBLE-01																																																						
IBD-01228	IBD-01228-WB-01	1	1457228	GSE32148															IBD-01228	IBD-01228-PBLE-01																																																						
IBD-01229	IBD-01229-WB-01	1	1457228	GSE32148															IBD-01229	IBD-01229-PBLE-01																																																						
IBD-01230	IBD-01230-WB-01	1	1457228	GSE32148															IBD-01230	IBD-01230-PBLE-01																																																						
IBD-01231	IBD-01231-WB-01	1	1457228	GSE32148															IBD-01231	IBD-01231-PBLE-01																																																						
IBD-01232	IBD-01232-WB-01	1	1457228	GSE32148															IBD-01232	IBD-01232-PBLE-01																																																						
IBD-01233	IBD-01233-WB-01	1	1457228	GSE32148															IBD-01233	IBD-01233-PBLE-01																																																						
IBD-01234	IBD-01234-WB-01	1	1457228	GSE32148															IBD-01234	IBD-01234-PBLE-01																																																						
IBD-01235	IBD-01235-WB-01	1	1457228	GSE32148															IBD-01235	IBD-01235-PBLE-01																																																						
IBD-00959	IBD-00959-CLN-01	1	1457228	E-MTAB-184															IBD-00959	IBD-00959-HFCLN-01																																																						
IBD-00959	IBD-00959-CLN-02	1	1457228	E-MTAB-184															IBD-00959	IBD-00959-REC-02																																																						
IBD-00961	IBD-00961-CLN-01	1	1457228	E-MTAB-184															IBD-00961	IBD-00961-CLN-01																																																						
IBD-00961	IBD-00961-CLN-02	1	1457228	E-MTAB-184															IBD-00961	IBD-00961-TCLN-02																																																						
IBD-00963	IBD-00963-CLN-01	1	1457228	E-MTAB-184															IBD-00963	IBD-00963-CLN-01																																																						
IBD-00917	IBD-00917-CLN-02	1	1457228	E-MTAB-184															IBD-00917	IBD-00917-CLN-02						CORTICOSTEROIDS																																																
IBD-00416	IBD-00416-CLN-01	1	1457228	E-MTAB-184															IBD-00416	IBD-00416-HFCLN-01						SULFASALAZINE																																																
IBD-00963	IBD-00963-CLN-02	1	1457228	E-MTAB-184															IBD-00963	IBD-00963-CLN-02																																																						
IBD-00925	IBD-00925-CLN-02	1	1457228	E-MTAB-184															IBD-00925	IBD-00925-SCLN-02						CORTICOSTEROIDS																																																
IBD-00965	IBD-00965-CLN-01	1	1457228	E-MTAB-184															IBD-00965	IBD-00965-HFCLN-01						MESALAMINE		B1																																														
IBD-00965	IBD-00965-CLN-02	1	1457228	E-MTAB-184															IBD-00965	IBD-00965-SCLN-02						SULFASALAZINE		B1																																														
IBD-00967	IBD-00967-CLN-01	1	1457228	E-MTAB-184															IBD-00967	IBD-00967-HFCLN-01						MESALAMINE		B1																																														
IBD-00967	IBD-00967-CLN-02	1	1457228	E-MTAB-184															IBD-00967	IBD-00967-SCLN-02						SULFASALAZINE		B1																																														
IBD-00970	IBD-00970-CLN-01	1	1457228	E-MTAB-184															IBD-00970	IBD-00970-HFCLN-01																																																						
IBD-00970	IBD-00970-CLN-02	1	1457228	E-MTAB-184															IBD-00970	IBD-00970-CLN-02																																																						
IBD-00971	IBD-00971-CLN-01	1	1457228	E-MTAB-184															IBD-00971	IBD-00971-HFCLN-01						MESALAMINE		B1																																														
IBD-00971	IBD-00971-CLN-02	1	1457228	E-MTAB-184															IBD-00971	IBD-00971-CLN-02						SULFASALAZINE		B1																																														
IBD-00973	IBD-00973-CLN-01	1	1457228	E-MTAB-184															IBD-00973	IBD-00973-HFCLN-01																																																						
IBD-00973	IBD-00973-CLN-02	1	1457228	E-MTAB-184															IBD-00973	IBD-00973-CLN-02																																																						
IBD-00974	IBD-00974-CLN-01	1	1457228	E-MTAB-184															IBD-00974	IBD-00974-HFCLN-01						MESALAMINE		B1																																														
IBD-00974	IBD-00974-CLN-02	1	1457228	E-MTAB-184															IBD-00974	IBD-00974-REC-02						SULFASALAZINE		B1																																														
IBD-00977	IBD-00977-CLN-01	1	1457228	E-MTAB-184															IBD-00977	IBD-00977-REC-01																																																						
IBD-00977	IBD-00977-CLN-02	1	1457228	E-MTAB-184															IBD-00977	IBD-00977-CLN-02																																																						
IBD-00979	IBD-00979-CLN-01	1	1457228	E-MTAB-184															IBD-00979	IBD-00979-REC-01																																																						
IBD-00979	IBD-00979-CLN-02	1	1457228	E-MTAB-184															IBD-00979	IBD-00979-HFCLN-02																																																						
IBD-00982	IBD-00982-CLN-01	1	1457228	E-MTAB-184															IBD-00982	IBD-00982-REC-01						MESALAMINE		B1																																														
IBD-00417	IBD-00417-CLN-01	1	1457228	E-MTAB-184															IBD-00417	IBD-00417-HFCLN-01						SULFASALAZINE																																																
IBD-00982	IBD-00982-CLN-02	1	1457228	E-MTAB-184															IBD-00982	IBD-00982-HFCLN-02						SULFASALAZINE		B1																																														
IBD-00984	IBD-00984-CLN-01	1	1457228	E-MTAB-184															IBD-00984	IBD-00984-HFCLN-01																																																						
IBD-00984	IBD-00984-CLN-02	1	1457228	E-MTAB-184															IBD-00984	IBD-00984-REC-02																																																						
IBD-00987	IBD-00987-CLN-01	1	1457228	E-MTAB-184															IBD-00987	IBD-00987-HFCLN-01																																																						
IBD-00987	IBD-00987-CLN-02	1	1457228	E-MTAB-184															IBD-00987	IBD-00987-REC-02																																																						
IBD-00423	IBD-00423-CLN-01	1	1457228	E-MTAB-184															IBD-00423	IBD-00423-HFCLN-01						SULFASALAZINE																																																
IBD-00423	IBD-00423-CLN-01	1	1457228	E-MTAB-184															IBD-00423	IBD-00423-HFCLN-01						CORTICOSTEROIDS																																																
IBD-00990	IBD-00990-CLN-01	1	1457228	E-MTAB-184															IBD-00990	IBD-00990-HFCLN-01						MESALAMINE		B1																																														
IBD-00990	IBD-00990-CLN-02	1	1457228	E-MTAB-184															IBD-00990	IBD-00990-REC-02						SULFASALAZINE		B1																																														
IBD-00991	IBD-00991-CLN-01	1	1457228	E-MTAB-184															IBD-00991	IBD-00991-HFCLN-01																																																						
IBD-00991	IBD-00991-CLN-02	1	1457228	E-MTAB-184															IBD-00991	IBD-00991-REC-02																																																						
IBD-00992	IBD-00992-CLN-01	1	1457228	E-MTAB-184															IBD-00992	IBD-00992-HFCLN-01						CORTICOSTEROIDS		B1																																														
IBD-00910	IBD-00910-CLN-02	1	1457228	E-MTAB-184															IBD-00910	IBD-00910-CLN-02						CORTICOSTEROIDS																																																
IBD-00992	IBD-00992-CLN-02	1	1457228	E-MTAB-184															IBD-00992	IBD-00992-REC-02						CORTICOSTEROIDS		B1																																														
IBD-01059	IBD-01059-PBMC-03	1	1457228	E-MTAB-331			Complete Remission												IBD-01059	IBD-01059-PBMC-03					410 Flare (124 days). SCCAI 8 - Failed to respond to Prednisolone. Completely responded to Acetarsol suppositories.   Offered Azathioprine but declined  elected to use cyclical AcetarsolA. Flare (404 days). SCCAI 12- Treated with Prednisolone and Acetarsol suppositories. Fully responded.    commenced MethotrexateA.	TOPICAL THERAPY							AZATHIOPRINE	124	Complete Remission	Complete Response																																						
